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These are palmy days for those of us 
concerned with platelet research" 
Daniel Deykin, 1974.
VPREFACE
There is growing evidence that blood platelets are involved in a number 
of pathological conditions, the best characterized of these being 
atherosclerosis which results in narrowing of the coronary arteries and is 
the lesion underlying clinically overt coronary heart disease. Coronary 
heart disease is a multifactorial disease and has at least eighteen 
reported risk factors associated with its development. Although 
controversy exists over some of these factors a number are well documented. 
If the platelet does play a key role in the initiation and progression of 
atherosclerosis, the determination of the effects of both positive and 
negative risk factors on platelet function may provide much needed 
information on effective means to control coronary heart disease which has 
reached epidemic proportions in many developed societies. This thesis 
contains such investigations and includes the examination of four 
dietary-related factors on platelet function.
The introductory Chapter includes a precis of the discovery and 
elucidation of platelet function and is followed by a detailed discussion 
of platelet composition, function and factors involved in regulating their 
activity; knowledge and understanding of such factors is a necessary 
prerequisite for the investigation of altered platelet function and the 
interpretation of the findings. The latter part of Chapter 1 describes 
certain aspects of coronary heart disease and the evidence for platelet 
involvement. Chapter 2 describes the materials and methods employed in the 
course of the investigations carried out.
Chapter 3 examines the effects of diets enriched in either saturated or 
polyunsaturated fats on human platelet function. The findings support the 
existing evidence for saturated fats being conducive to platelet 
activation; in addition the results would suggest that this is an in vivo
vi
phenomenon.
The experiments described in Chapter 4 were conducted in order to 
examine the possibility that platelets are affected by postprandial 
alimentary lipaemia which has been reported to have atherogenic properties; 
however, no evidence of altered platelet activity could be found during the 
postprandial state.
Chapter 5 examines the effects of hypercholesterolaemia on platelet 
composition and their ability to accumulate cyclic AMP in response to three 
prostaglandins. Although no evidence of altered platelet composition was 
found, impaired responses to the three prostaglandins was demonstrated.
Chapter 6 examines the effect of eicosapentaenoic acid on platelet 
function. This polyunsaturated fatty acid, which is structurally similar 
to arachidonic acid, was found to inhibit aggregation directly and also 
acted as a substrate for arterial tissue which converted it into a 
prostacyclin-like substance which also resulted in inhibition of platelet 
aggregation and elevation of platelet cyclic AMP.
Chapter 7 discusses the findings and implications of Chapters 3-6 in 
relation to the role played by platelets in atherosclerosis and coronary 
heart disease. A brief discussion of several methodological aspects of 
platelet function studies is also included.
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CHAPTER 1
GENERAL INTRODUCTION
21.1 THE PLATELET
1.1.1 Milestones in platelet studies
"On March 7, 1842 at a session of the "Academie des Sciences" of Paris 
during an account of studies on the microscopy of blood Donne stated in 
clear terms that there existed in the blood red and white globules and 
little globules ("globulins"). There seems to be no earlier record of the 
recognition of the platelet as a formed element of the blood" (Tocantins, 
1948).
In the same year three other investigators independently reported the 
presence in blood of what we now know as platelets (Addison, 1842; Gerber, 
1842; Simon, 1842). Thus 1842 may be regarded as the inceptive year of 
platelet studies. There followed forty years of observation and 
speculation on the activity and function of platelets, but it was 
Bizzozero, who in 1882 put matters into perspective by describing in detail 
the adhesion of "plättchen" to damaged arterial tissue and the formation 
of a thrombus, the white portion of which was predominantly platelets. In 
1886 Eberth and Schimmelbusch coined the term "viscous metamorphosis" to 
describe the transformation of platelets from a labile state to an active 
adhesive state which was a prerequisite for aggregation.
In the following nineteen years the role played by platelets in clot 
formation was further documented and in 1905 Morawitz delineated 
haemostasis with the platelet playing a central role in thrombin formation 
and hence, blood coagulation. After Morawitz’s treatise there followed a 
period of almost fifty years during which few publications appeared 
regarding platelet function (Liischer, 1978). It was in 1952 that this 
dearth of interest prompted a group of interested individuals under the 
chairmanship of Walter H. Seegers to organise a one day conference on 
platelets that "they might attract attention to a neglected area" (Seegers,
1976). In the following ten years a number of important landmarks may be 
noted which set the scene for present day research.
The release of 5-hydroxytryptamine (5-HT, serotonin) from platelets 
during thrombin induced viscous metamorphosis was originally reported by 
Bigelow (1954) and subsequently demonstrated to be a specific "release 
reaction" by Grette (1962). The selective release of platelet 
constituents, rather than lysis, was confirmed by electron microscopy 
(Kjaerheim and Hovig, 1962). In the same year Gaarder et al. (1962) 
demonstrated that a previously described factor released from red blood 
cells and platelets (Hellem, 1960; 011gard, 1961), which would induce 
platelet aggregation, was in fact adenosine diphosphate (ADP). Born (1962) 
and Born et al. (1963) confirmed these observations and also described the 
fundamental requirements and kinetics of platelet aggregation. He made 
this possible by introducing the platelet aggregometer (a slightly modified 
Unicam spectrophotometer) and in doing so instigated the most useful and 
widely used instrument in platelet function studies to the present day.
Since the early 1960s a vast amount of literature has been published 
on the physiology and pathology of the platelet. I have selected two areas 
for brief discussion which are particularly relevant to this thesis.
(i) In 1974 Hamberg and Samuelsson described the prostaglandin 
endoperoxides PGG2 and PGH2 . The selective metabolism of 
PGH2 to thromboxane A2 by the platelet and to prostacyclin by 
arterial tissue have probably been the most significant 
discoveries of the decade in terms of the control of platelet 
function.
(ii) A second area of research which has yielded exciting information 
was initially reported by Ross and colleagues in 1974. These 
workers described a platelet-derived growth factor (PDGF) which is
4an absolute requirement for the proliferation of arterial smooth 
muscle cells (SMC) grown in culture. In vivo arterial SMC 
proliferation is an important characteristic of the atherosclerotic plaque. 
Hence, evidence for platelet involvement in the atherogenic process was 
greatly reinforced. Detailed discussion of these observations will follow 
in subsequent chapters.
1.1.2 Ultrastructure and composition
Blood platelets vary from 2-5 pm in diameter and from 2-4 x 10^/pl 
blood, and they are derived from megakaryocytes of bone marrow (Behnke, 
1970).
The structural physiology of the platelet is a field that has 
contributed greatly to our understanding of platelet function and 
dysfunction. Determination of the structural physiology of the platelet 
has been made possible by use of the highly specialized techniques of 
electron microscopy, cytochemistry, immunocytochemistry, biochemistry and 
physiology. For convenience of discussion the platelet may be divided into 
three zones (White, 1979).
1.1.2.1 The peripheral zone
The peripheral zone may be regarded as having three distinct areas: 
the outer plasmatic atmosphere, the glycocalyx, and the inner platelet 
membrane (Jamieson and Smith, 1976).
The outer plasmatic atmosphere is composed of a number of coagulation 
factors which are thought to be involved in platelet activation. A number 
are loosely bound and may be removed by washing procedures (Ardlie and Han, 
1974).
The glycocalyx is 20-50 nm in thickness and is rich in glycoproteins. 
By means of sodium dodecyl sulphate-polyacrylamide gel electrophoresis four
5major glycoproteins have been identified (Nachman and Ferris, 1972;
Phillips, 1972; Phillips et al., 1975). It is thought to be the 
carbohydrate residues of these glycoproteins that are observed as the 
"fluffy" coat at the platelet periphery (Holmsen, 1972; Jenkins and 
Clemetson, 1977). The glycocalyx, in addition to accommodating a thrombin 
receptor (Tollefsen et al., 1974), is thought to be the portion of the 
platelet that is transformed from a non-adhesive to a "sticky" surface 
which is a prerequisite for platelet adhesion and aggregation. Evidence 
for the role of the glycocalyx in this process is threefold: the outer
fluffy coat and ability to aggregate are specific characteristics of the 
platelet (Holmsen, 1972); sites of platelet-platelet adhesion stain 
specifically for carbohydrate (Holmsen, 1972); thirdly, studies of certain 
haemorrhagic disorders have demonstrated a reduction or absence of specific 
surface glycoproteins resulting in defective platelet adhesion, with no 
apparent effect on other platelet functions (Nurden and Caen, 1974; 1975;
Phillips et al., 1975). (Section 1.1.4).
The platelet membrane is similar in most respects to the basic plasma 
membrane of most cells, having a trilaminar appearance and being 7-9 nm in 
thickness. The presence of the open, or surface-connected, canalicular 
system results in the characteristic sponge-like appearance of the platelet 
surface. The surface-connected canalicular system is a tortuous system of 
membrane-lined channels that invaginate deep into the platelet and perhaps 
allows more efficient communication between the platelet and its external 
environment.
The platelet membrane system is not confined to the peripheral zone as 
it contributes to such structures as the dense tubular system (DTS) and 
Golgi apparatus and has associated receptors and enzymes. The receptors 
appear to transmit stimuli by a large number of agents, both stimulatory 
and inhibitory, to the effector site within the platelet. Receptors for
6the following substances have been reported to be present on the platelet 
surface: ADP, 5-HT, catecholamines, thrombin, collagen, vasopressin,
acetylcholine, prostaglandins, adenosine and isoprenaline. For a review of 
platelet receptors see Mills and Macfarlane (1976). More recently, 
receptors for the coagulation factor Xa (Miletich et al., 1977) and insulin 
(Hajek et al., 1979) have been reported.
Numerous enzymes have also been reported to be associated with the 
platelet membrane system such as phospholipases, cyclo-oxygenase and 
adenylate cyclase. In addition to providing a site for enzyme activity the 
membrane may also provide the substrates for certain enzymes, eg. the DTS 
membranes contains substantial amounts of arachidonic acid which may be 
liberated by specific lipases and act as substrate for the enzymes 
concerned with prostaglandin synthesis.
Further details of membrane-associated enzymes and substrates are 
discussed in subsequent sections.
1.1.2.2 The Sol-gel zone
The sol-gel zone of the platelet is a viscous matrix containing 
cytoplasmic enzymes eg. lactate dehydrogenase; metabolic substances eg. 
ADP, ATP (adenosine triphosphate) and glycogen granules; storage 
organelles; a variety of fibre systems and non-specific particles which 
have been phagocytosed by the platelet (Holmsen, 1972).
The fibre systems include microtubules and microfilaments which are 
thought to maintain the "resting" discoid appearance of the platelet and 
are involved in shape change, pseudopod formation, internal contraction and 
secretion (Crawford, 1976; White, 1979).
/1.1.2.3 The organelle zone
The organelle zone is not a discrete area as such, but is distributed 
throughout the sol-gel zone in the form of storage organelles, 
mitochondria, an "occasional" Golgi complex and the DTS. Platelets contain 
no nuclei, and mitochondria vary in number from 1-6 per platelet, are 
small, and contain few cristae relative to other cells (Hovig, 1968).
The DTS is a membranous structure found at the periphery of the 
sol-gel zone and plays an important role in modulating platelet activity. 
This is achieved by two closely associated, yet distinguishable mechanisms. 
One important function of the DTS is thought to be its ability to control 
the cytoplasmic level of calcium ion (Ca^+) level. Ca^+ is involved in 
several aspects of platelet aggregation, and the appearance of Ca^+ in 
the cytoplasm may account for the morphological manifestations of platelet 
activation (Lüscher and Massini, 1975). The DTS, by its ability to bind 
and release Ca^+, controls the cytoplasmic concentration of Ca^+ and 
thereby aggregation. The presence of Ca^+ storage vesicles may explain 
the ability of the DTS to control intracellular Ca^+ levels (Statland et^  
al. , 1969; Robblee, 1973; White, 1979).
The second important aspect of the DTS is concerned with the 
metabolism of arachidonic acid. The platelet membrane systems, including 
the DTS, are a rich source of arachidonic acid (Marcus et al., 1969) which 
may be released by Ca^+-dependent phospholipases and metabolized by DTS 
associated enzymes (Gerrard et al., 1976) to prostaglandins and 
thromboxanes which induce further aggregation and release. This action has 
been hypothesized to be a function of their Ca^+-mobilizing properties 
(Gerrard e t a l . , 1977, 1978). The DTS may therefore be regarded as
holding an eminent and complex role in the modulation of platelet function.
8Platelet storage organelles are distinguished from glycogen granules 
by the presence of a surrounding trilaminar membrane. Release of their 
constituents is by specific secretion involving membrane fusion and 
exocytosis and is a characteristic of the second phase of adrenaline- and 
ADP- induced aggregation.
Based on electron microscopy, platelet storage organelles were 
classically divided into two classes, namely dense bodies and a-granules 
(Holmsen, 1972; Weiss, 1975). However, with the development and 
application of more refined techniques it is now possible to distinguish at 
least four types of storage organelles (Fukami and Salganicoff, 1977). The 
most dense, both visually (after electron microscopy) and physically (by 
relative sedimentation rate), are known as dense bodies and contain 
non-metabolic ADP and ATP, 5-HT, catecholamines, Ca^+ and pyrophosphate 
(Fukami and Salganicoff 1977; Da Prada and Picotti, 1979). The functions 
of these released substances are be discussed in subsequent sections.
Human platelet dense bodies have not been reported to contain any of the 
platelet-secreted proteins; however, Joist et al. (1976a) have reported 
antiplasmin activity associated with the release of 5-HT from pig 
platelets.
The second class of storage organelles found in platelets are also 
electron dense, but less so than dense bodies, and are regarded as 
non-lysosomal a-granules. These organelles contain "platelet-specific 
proteins" which occur predominantly in the platelet (Niewiarowski, 1977). 
The development of highly sensitive and specific radioimmunoassays (RIA) 
has qualified use of the term platelet-specific (Niewiarowski et al., 1976; 
Ludlam, 1979) and has enabled extraplatelet concentrations of the proteins 
to be used as markers of platelet activation. Two such proteins are 
platelet factor 4 (PF^), originally named by Deutsch et al. (1955) and 
8-thromoglobulin (ß-TG), a term coined by Moore et al. (1975). These are
9probably the terms most familiar to workers in the field. However, based 
on heparin-binding studies Niewiarowski (1977) has proposed the terms 
high-affinity and low-affinity PF4 for PF4 and 3-TG respectively.
The earliest and perhaps best defined property of PF4 is its ability 
to neutralize the anticoagulant activity of heparin. Based on observations 
by Conley et al. (1948) that heparin activity was related to the platelet 
count, van Creveld and Paulssen (1951) demonstrated that platelets contain 
heparin-neutralizing activity (HNA). PF4 has also been described as 
having paracoagulant properties but this is a point of conjecture (Gjesdal, 
1977). More recently, PF4 has been described as having anti-collagenase 
activity (Hiti-Harper et al., 1978), but as yet, no well defined 
physiological role for PF4 has been documented. This is also true for 
8“TG, which is stored and released together with PF4 (Dawes et al., 1978; 
Witte et al., 1978; Fukami et al., 1979). However, a recent report on the 
ability of 8~TG to specifically bind to the endothelial cell and inhibit 
the release of prostacyclin may lead to exciting developments (Hope et al., 
1979).
A third protein, which is thought to be stored and released together 
with PF4 and 8-TG is the PDGF. Although the evidence for the precise 
site of storage of the PDGF is not unequivocal, it is highly suggestive 
(Weiss et al., 1977; Witte et al., 1978; Linder et al., 1979). The PDGF 
is an absolute requirement for the proliferation of cultured arterial SMC 
(Ross et al., 1974). The relevance of this observation to the role of 
platelets in haemostasis and atherosclerosis will be discussed in 
subsequent sections (1.1.3.2; 1.3.2.1; 1.3.3.1)
Fibrinogen has been reported to be stored in the same a_granule as 
PF4 (Broekman et al., 1975; Lopaciuk et al., 1976) and is a requirement 
for normal platelet aggregation, but as fibrinogen is also found in plasma,
10
the relevance of fibrinogen secretion by the platelet is not completely 
understood.
The second class of a-granules found in the platelet are lysosomal in 
nature and contain numerous hydrolytic enzymes including glycosidases, 
proteinases, phosphatases and sulphatases. Enzyme distribution data 
indicate that platelet lysosomes may be subdivided into two distinct types 
(Fukami and Salganicoff, 1977). The roles of released platelet lysosomal 
enzymes have not been fully established, but they may be involved in both 
physiological and pathological processes. Lysosomal enzymes have been 
implicated in the phagocytic and inflammatory aspects of platelet function 
(Gordon, 1975; Ehrlich and Gordon, 1976).
"There may well be other unresolved substances stored in other types 
of platelet granules, since it is axiomatic that one usually sees only that 
for which one searches" (Fukami and Salganicoff, 1977).
1.1.3 Platelet function
1.1.3.1 Haemostasis
An important and well documented aspect of platelet function is 
haemostasis, i.e. the cessation of blood loss from a damaged blood vessel. 
Within seconds of disruption of the endothelium the subendothelial tissues 
become covered with a single layer of platelets. The subendothelial 
tissues which induce platelet adhesion include collagen, basement membrane 
and the microfibrils around elastin (Baumgartner et al., 1976); however, 
it appears that of these tissues only collagen is capable of initiating 
subsequent platelet events (Section 1.2.1)
Following the contact phase, the platelet enters a contractile phase, 
characterized by transformation from a discoid to a spherical form with the 
development of spikes and pseudopods. Concomitantly, the marginal
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microtubules and microfilaments migrate towards the centre of the platelet 
encircling the storage organelles (White, 1968; Gerrard and White, 1976). 
Centralization of the storage organelles is accompanied by secretion of 
their contents into the surface connecting open canalicular system and 
consequently into the external environment, i.e. the release reaction. 
However, the release reaction should not be regarded as an absolute 
phenomenon as sequential release of individual storage organelle contents 
may occur depending on the intensity of stimulus occuring (Holmsen et al., 
1969; Holmsen, 1977a; Kinlough-Rathbone et al., 1977a).
In addition to the release of storage organelle contents the activated 
platelet also releases metabolites of arachidonic acid in particular 
PGG2/H2 (Hamberg et al., 1974; Smith et al. , 1974) and TXA2 (Hamberg 
et al. , 1975; Smith et al., 1976), (Section 1.2.7.1). These substances, 
together with a number of dense body constituents, notably ADP, Ca^+ , 
adrenaline and 5-HT, result in further platelet activation and adhesion to 
the layer of platelets covering the subendothelium; this is the process of 
platelet aggregation.
During the morphological changes associated with adhesion and the 
contractile phase the platelets develop coagulant activity, van Creveld 
and Paulssen (1951) originally named this, and associated anti-heparin 
activity, platelet factor 3 (PF3). However, it was subsequently shown 
that these two properties could be divorced; the coagulant activity 
retained the term PF3, while anti-heparin activity was renamed PF4 
(Deutsch et al., 1955). PF3 has been demonstrated to be a 
phospholipoprotein which becomes available on the surface of activated 
platelets (Hardisty and Hutton, 1966; Joist et al., 1974).
The availability of coagulant activity on the platelet provides a 
catalytic surface for several major steps in the coagulation sequence which
12
may be i n i t i a t e d  by c o n t a c t  w i t h  t h e  exposed  s u b e n d o th e l iu m  and a c t i v a t e d  
p l a t e l e t s  ( t h e  i n t r i n s i c  pathway) a n d / o r  t h e  r e l e a s e  o f  t h r o m b o p l a s t i c  
t i s s u e  f a c t o r  f rom t h e  damaged v a s c u l a t u r e  ( t h e  e x t r i n s i c  p a th w a y ) .
P l a t e l e t  c o a g u l a n t  a c t i v i t y  i s  i n v o l v e d  i n  t h e  a c t i v a t i o n  of  f a c t o r  X t o  Xa 
and I I  t o  I l a  ( t h r o m b i n ) .  There  a r e  t h r e e  major  c o n s eq u e n c e s  of  th rom b in  
f o r m a t i o n :
( i )  I n i t i a t i o n  of  a d d i t i o n a l  p l a t e l e t  a g g r e g a t i o n  and r e l e a s e ;
( i i )  C a t a l y s i s  of  t h e  f o r m a t i o n  of  f i b r i n  monomers f rom f i b r i n o g e n ;
( i i i )  A c t i v a t i o n  of  f a c t o r  X I I I  t o  X H I a  which  r e s u l t s  i n  t h e  
p o l y m e r i z a t i o n  and s t a b i l i z a t i o n  o f  f i b r i n  ( S c h w a r t z  e t  a l . , 
1973) .
These a c t i o n s  r e s u l t  i n  a d d i t i o n a l  p l a t e l e t  d e p o s i t i o n  and th e  
p l a t e l e t  p lug  becoming enmeshed w i t h  p o ly m e r iz e d  f i b r i n .  I t  has  been  
d e m o n s t r a t e d  t h a t  p l a t e l e t s  a d h e r e  to  p o l y m e r i z i n g  f i b r i n  and t h i s  may l e a d  
t o  f u r t h e r  p l a t e l e t  d e p o s i t i o n  ( N iew ia row sk i  e t  a l . , 1972) .
The p l a t e l e t - f i b r i n  mass may now be r e g a r d e d  a s  a c o n s o l i d a t e d  
h a e m o s t a t i c  p l u g ,  t h e  f u l l y  p o ly m e r iz e d  f i b r i n  p r e s e n t i n g  a r e l a t i v e l y  
i n e r t  s u r f a c e  to  c i r c u l a t i n g  p l a t e l e t s  (Hovig e t  a l . ,  1968 ) .  V a r io u s  
a s p e c t s  of h a e m o s t a s i s  have been  r ev i e w e d  i n  d e t a i l  by o t h e r s  (Walsh ,  1974; 
M us ta rd  and Packham, 1977; Mason and Saba ,  1978) .
1 . 1 . 3 . 2  R e s t o r a t i o n  and m a i n te n a n c e  o f  v a s c u l a r  i n t e g r i t y
The h a e m o s t a t i c  mechanisms j u s t  d e s c r i b e d  may o n l y  be viewed as  a 
t e m p o r a r y  measure  to  p r e v e n t  b lood  l o s s .  In  o r d e r  t o  r e t u r n  to  a normal  
c o n t r a c t i l e  o rg an  t h e  b lood  v e s s e l  must unde rgo  r e p a i r  p r o c e s s e s  which 
r e q u i r e  f u r t h e r  p l a t e l e t  i n v o l v e m e n t .
Weksle r  and Coupal (1973)  have r e p o r t e d  t h a t  a p l a t e l e t  d e p e n d e n t  
serum f a c t o r ( s )  e x i s t s  which i s  c h e m o t a c t i c  f o r  l e u c o c y t e s  and may be
responsible for the attraction of neutrophils which invade the haemostatic 
plug and are responsible for the inflammatory response associated with 
tissue damage. Factors such as TXB2 and HETE (Section 1.2.7.1), which 
are produced during platelet aggregation, have been reported to have 
chemotactic activity (Turner et al., 1975; Kitchen et al., 1978). Other 
factors which mediate chemotaxis and subsequent inflammation have been 
reviewed by Ryan and Majno (1977) and platelets may be a source of such 
factors. Neutrophils and macrophages ultimately remove platelet debris and 
fibrin (Jorgensen et al., 1967).
Subsequent repair of the vascular lesion is poorly understood (Mason 
and Saba, 1978); however, the release from platelets of factors which 
stimulate the growth of cultured fibroblasts and SMC (Ross et al., 1974; 
Rutherford and Ross, 1976; Witte et al., 1978; Pohjanpelto, 1979) may be 
of importance since these cells are major structural components of the 
vessel wall which require regeneration in the damaged area. Endothelial 
cells may also respond in a similar manner (Maca et al., 1977; D’Amore and 
Shepro, 1977). In addition, platelet factors appear to cause migration of 
endothelial cells, possibly to the de-endothelialized area resulting in 
restoration of the normal endothelial barrier (Maca et al., 1977; Wall ejt 
al., 1978).
The proliferative and migratory responses described are also thought 
to maintain chronic vascular integrity. A number of in vivo and in vitro 
studies have demonstrated that in the absence of platelets vascular 
homeostasis is disrupted in other ways eg. development of endothelial gaps, 
increased permeability and increased vascular fragility (Gimbrone et al., 
1969; Gore et al., 1970; Kitchens and Weiss, 1975).
In addition to haemostasis and maintainance of vascular integrity 
platelets have been implicated in other physiological processes and are
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considered to be "an integral part of the entire defense system of the 
body" (Caen et al., 1977).
1.1.4 Platelet dysfunction
On consideration of the major role played by the platelet, namely 
haemostasis, it is not surprising that the best characterized disorders of 
platelet function are haemorrhagic or bleeding disorders resulting from 
hypofunction. Platelet disorders may be qualitative or quantitative in 
nature (Weiss, 1975; Lüscher and Barnhart, 1977; Mason and Saba, 1978; 
White and Gerrard, 1978).
In recent years, with a greater understanding of the pathogenesis of 
obstructive vascular diseases, it has become apparent that the haemostatic 
process may be disordered and diseases such as thrombosis and 
atherosclerosis may be considered to be aberrant forms of haemostasis 
involving platelet "hyperfunction" and other factors.
1.2 MODULATION OF PLATELET ACTIVITY
A knowledge of factors controlling platelet activity is fundamental to 
understanding the role played by platelets in both physiological and 
pathological processes. The following section summarizes factors known to 
be involved in the control of platelet activity.
1.2.1 Connective tissue
As described earlier, platelet interaction with subendothelial
connective tissue is the initial event leading to platelet activation and 
subsequent haemostasis.
1.2.1.1 Collagen
Collagen is the major subendothelial connective tissue capable of
initiating platelet activity. The collagen molecule is predominantly
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helical in structure, and platelet release and aggregation appears to be 
related to its quaternary structure (Puett et al., 1973; Brass and 
Bensusan, 1974; Jaffe and Deykin, 1974).
Four types of collagen have been identified and are characterized by 
their amino acid sequence and subunit number. Type III appears to be the 
most potent platelet activator (Balleisen et al., 1975) and is the major 
collagen type found in the internal elastic lamina (Gay et al.,
1975). Adhesion of human platelets to collagen does not have an absolute 
requirement for plasma cofactors, but is enhanced in the presence of Ca^+ 
and fibrinogen (Lyman et al. , 1971; Baumgartner, 1972; 1974; Cazenave e_t
al. , 1973). Adhesion involves glycoproteins of the glycocalyx, and 
possibly the von Willebrand factor. The absence of these factors in the 
Bernard-Soulier syndrome and von Willebrand's disease is associated with 
bleeding disorders resulting from defective platelet adhesion (Tschopp jrt 
al. , 1974; Weiss et al., 1974; Baumgartner et al., 1976). More recently, 
fibronectin, a glycoprotein found in platelets and plasma which binds 
collagen, has been implicated in platelet-collagen interaction (Plow e_t 
al. , 1979; Ruoslahti and Hayman, 1979), but may only play a minor role 
(Santoro and Cunningham, 1979). Although Ca^+ is not required for 
adhesion or release, subsequent aggregation is dependent upon extracellular 
Ca^+ and is mediated by the release of arachidonic acid metabolites and 
dense body constituents (Holmsen, 1977). Aspirin and other non-steroidal 
anti-inflammatory agents can inhibit collagen-induced aggregation, but this 
may be overcome by higher concentrations of collagen, suggesting that 
collagen may initiate release and aggregation by at least two pathways, one 
of which is cyclo-oxygenase independent (Zucker and Peterson, 1970; Nyman, 
1977).
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1.2.1.2 Elastin
Elastin is a component of both the internal elastic lamina and the 
intima (Jaffe, 1976) and when exposed by collagenase and trypsin digestion 
appears to be relatively unreactive to platelets (Baumgartner, 1974a).
1.2.1.3 Glycoproteins
Glycoproteins are found throughout the blood vessel wall and may be 
organised into non-collagenous microfibrils (Ross and Bornstein, 1969). 
Evidence suggests that platelets will adhere to such microfibrils but 
subsequent aggregation does not occur (Baumgartner and Muggli, 1976).
1.2.1.4 Proteoglycans
Proteoglycans are found throughout the vessel wall and appear to be 
non-reactive to platelets although platelet-proteglycan interaction has not 
been systematically studied (Jaffe, 1976).
1.2.2 Coagulation factors
Platelet-coagulation factor interaction is central to haemostasis and 
there is growing evidence that coagulation factors mediate several aspects 
of platelet function; the von Willebrand factor, and possibly fibrinogen, 
are necessary for the normal adhesion of platelets to collagen. In 
addition fibrinogen is required for subsequent aggregation induced by all 
aggregating agents (Deykin et al., 1965; Inceman et al., 1966).
During the haemostatic process thrombin is formed by the interaction 
of coagulation factors on the platelet surface. In addition to fibrin 
formation and stabilization, thrombin is a potent inducer of aggregation 
and release. Further, it has been suggested that small amounts of thrombin 
are formed on the platelet surface prior to the formation of sufficient 
thrombin in the plasma to induce fibrin formation and clotting (Majerus
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et al., 1976; Shuman et al. , 1976). These small amounts of thrombin may 
be a stimulus for the release of platelet constituents with consequent 
aggregation. Huzoor-Akbar and Ardlie (1977) have suggested that thrombin 
formation on the platelet surface mediates platelet aggregation induced by 
collagen and ADP.
Platelets have been demonstrated to have specific thrombin receptors 
which are located in the glycocalyx (Tollefsen et al. , 1974). Binding to 
this receptor appears to be the primary event leading to platelet 
activation by thrombin (Shuman and Majerus, 1975); after binding, thrombin 
may induce aggregation by at least three pathways which are dependent on:
(i) Formation of arachidonic acid metabolites (Malmsten et al., 
1975).
(ii) Release of ADP (Haslam, 1974);
(iii) Neither (i) or (ii), and possibly involving direct Ca^+ 
mobilization (Macfarlane and Mills, 1975; Kinlough-Rathbone 
et al., 1977b; Packham et al., 1977; Lapetina et al., 1978).
1.2.3 Anticoagulants
As several coagulation factors are involved in the activation of 
platelets it is not surprising that a number of anticoagulants have 
antiplatelet action. The most commonly used anticoagulant is heparin which 
activates antithrombin III (AT III) a naturally occuring inhibitor of the 
following coagulation factors: IXa, Xa, XIa, Xlla and Ila (thrombin). In
the absence of heparin AT III has very low activity, but in the presence of 
trace amounts of heparin the inhibitory activity is greatly enhanced.
(Damus et al., 1973; Rosenberg and Damus, 1973).
Reports on the effect of heparin on platelet function are confusing. 
Recently Wessler and Gitel (1976) stated: "although a rich literature
exists on platelet function it is still not clear whether heparin in vivo
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prevents or facilitates platelet aggregation". The controversy would 
appear to be a function of one or more of the following factors: heparin
source and concentration, or the presence of other anticoagulants eg. 
citrate.
A second question concerning heparin is whether or not it is a 
naturally circulating anticoagulant. It is associated with various organs 
of the body, but no reports to date have demonstrated conclusively that 
free heparin is present in the blood. Related sulphated 
mucopolysaccharides do exist, notably on the endothelial cell (Buonassi, 
1973; Moritani and Ohta, 1973; Berenson et al., 1974) and have 
demonstrable heparin-like activity (Teien et al., 1976; Hatton et al., 
1978) and may play physiological roles in fibrin- or platelet-endothelial 
cell interaction (Teien, 1979).
1.2.4 Calcium
Extracellular Ca^+ is not required for platelet adhesion to 
collagen, shape change (Skoza et al., 1967; Born, 1970) or the release 
reaction induced by collagen or thrombin (Spaet and Zucker, 1964; 
Mueller-Eckhardt and Lüscher, 1968; Roblee et al., 1973); however, 
subsequent aggregation does have an absolute requirement for Ca^+ (Hovig, 
1964). Other agents, such as ADP and adrenaline, do require Ca^+ for the 
induction of release (Massini, 1977).
In contrast to extracellular Ca^+ , intracellular Ca^+ appears to 
be involved in each step of platelet activation. This has been 
demonstrated by use of ionophores, agents which aid the flux of Ca^+ 
across membranes (Pressman, 1976). Ionophores such as A23187 increase 
platelet cytoplasmic Ca^+ and the following aspects of platelet 
activation may be induced: shape change (Gerrard et al., 1974);
aggregation independent of released ADP or arachidonic acid metabolites
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(Kinlough-Rathbone et al., 1977a); the release reaction (White et al.,
1974) and clot retraction (Massini and Löscher, 1974). Use of ionophores 
has also demonstrated that sufficient intracellular Ca^+ may be derived 
from sites independent of the dense bodies (namely the DTS) as ionophore- 
induced aggregation in the absence of extracellular Ca^+ is normal in 
patients whose platelets are deficient in these Ca^+ storage organelles 
(White et al. , 1974).
Ca^+ antagonists such as TMB-8 (8-(N,N-diethylamino)-octyl-3,4,5- 
trimethoxybenzoate) have also been useful in elucidating the role of 
intracellular Ca^+ in platelet function (Rittenhouse-Simmons and Deykin, 
1978).
1.2.5 Biogenic amines
1.2.5.1 5-HT
Platelets are the major source of 5-HT in the blood and it is released 
from the dense bodies during platelet aggregation. The platelet is 
efficient at accumulating 5-HT which is achieved by both active and passive 
transport mechanisms (Drummond, 1976). The major haemostatic functions of 
5-HT are twofold; firstly, it is a potent vasoconstrictor and this action 
may aid haemostasis; secondly, 5-HT may induce platelet aggregation. In 
vitro aggregation of human platelets by 5-HT is generally weak and 
reversible in nature (Mitchell and Sharp, 1964) and does not appear to 
induce the release reaction, but will potentiate aggregation induced by ADP 
or adrenaline (Baumgartner and Born, 1968).
1.2.5.2 Catecholamines
Adrenaline, noradrenaline and dopamine are the three catecholamines 
found in human platelets; they are stored and released together with ATP, 
ADP, Ca^+ and 5-HT as dense body constituents (Born and Smith, 1970;
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Da Prada and Picotti, 1979).
The evidence for platelet shape change induced by catecholamines is 
controversial and awaits further study (Drummond, 1976); however, 
adrenaline and noradrenaline will induce biphasic aggregation (O'Brien, 
1963; MacMillan, 1966)
The primary phase of aggregation induced by catecholamines is believed 
to be mediated by an ot-adrenergic receptor which may be blocked 
competitively by a-antagonists such as phentolamine and dihydroergotamine 
(Mills and Roberts, 1967; Rysanek et al., 1968). Subsequent secondary 
aggregation is dependent upon released ADP and other substances, and once 
initiated is independent of adrenaline and the a-receptor (MacMillan, 1966; 
Mills et al., 1968; Rossi and Levin, 1973; Macfarlane and Mills, 1975). 
Catecholamines can potentiate platelet aggregation induced by other agents 
such as ADP (Ardlie et al., 1966; Mills and Roberts, 1967), 5-HT, thrombin 
and collagen (Baumgartner and Born, 1968; Thomas, 1968).
1.2.6 Adenine nucleotides
The major non-cyclic adenine nucleotides found in, and affecting, 
platelets are ATP and ADP. Approximately two thirds of the ADP and ATP 
are metabolically non-active and are stored in the dense bodies; the 
remainder is found in a metabolically active pool distributed in the 
cytoplasm, mitochondria and membranes (Holmsen, 1972).
1.2.6.1 ATP
ATP is involved in both resting and-active aspects of platelet 
function. It is required by the Ca^+ extrusion pump which is thought to 
maintain the platelet in a non-reactive state. ATP may be converted to 
cyclic adenosine 3',5'-monophosphate (cyclic AMP) which also regulates 
platelet reactivity (Section 1.2.8.1). ATP is considered to be the energy
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source for the following aspects of platelet function: shape change,
aggregation, secretion and clot retraction (Holmsen, 1977b).
1.2.6.2 ADP
In contrast to ATP, the most important pool of ADP appears to be that 
found in, and released from, dense bodies. The release of ADP is an 
important, although non-absolute requirement for platelet aggregation; as 
thrombin may induce aggregation that is independent of the release of ADP 
(Section 1.2.2). Under normal physiological conditions the release of ADP 
induces the activation and deposition of platelets, indeed subjects with 
storage pool disease, in which ADP is either absent or unreleasable from 
the dense bodies, demonstrate a mild bleeding disorder (Hardisty, 1977).
1.2.7 Prostaglandins and thromboxanes
Prostaglandins and thromboxanes are oxygenated metabolites of 
polyunsaturated fatty acids (PUFA) containing twenty carbon atoms (C2o)«
The C20 PUFA may be obtained directly from the diet but they are usually 
synthesized in the body by chain elongation and desaturation of essential 
dietary precursors (Figure 1.1). Depending upon the number of double bonds 
associated with the C20 PUFA, which predetermines the resulting number in 
the product, three classes of derivatives may be produced (Figure 1.1):
(i) The monoenoic series (PG^/TX^);
(ii) The dienoic series (PG2/TX2);
(iii) The trienoic series (PG3/TX3).
In humans the dienoic series (arachidonic acid-derived) are the most 
common, although under certain dietary regimens this may be altered in some 
tissues (Chapter 6). Arachidonic acid is transported in the blood bound to 
albumin and is subsequently incorporated into the membranes of all tissues 
of the body (Ramwell et al., 1977), notably at the 2-position of
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Figure 1.1 Sources and metabolism of fatty acids
All the fatty acids shown may be obtained from the diet. The 
non-essential fatty acids (centre pathway) may be produced de-novo by 
mammals from protein or carbohydrate (CBH) sources. Linoleic and linolenic 
acids, the parent fatty acids of each series (upper and lower pathways), 
may only be produced by non-animal species but subsequent chain elongation 
and desaturation may occur in humans and the majority of other animal 
species.
dienoic prostaglandins and 
thromboxanes
monoenoic prostaglandins and 
thromboxanes
18:2*
DHCLA*** AA****n-6**
linoleic acid
18: 2— -2 0:2—*2 0: 3
18:0DIET--►PROTEIN
linolenic acid
trienoic prostaglandins and 
thromboxanes ___
*Each fatty acid is shown as carbon number followed by number of double 
bonds; thus, linoleic acid is an 18 carbon fatty acid with 2 double bonds
**n-3; n-6; n-9 Refer to the position of the first double bond from the 
methyl terminal
*** DHGLA Dihomo-y-1inolenic acid (8,11,14-eicosatrienoic acid)
**** AA Arachidonic acid (5,8,11,14-eicosatetraenoic acid)
***** EPA Eicosapentaenoic acid (5,8,11,14,17-eicosapentaenoic acid)
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phospholipids. The ubiquity of arachidonic acid in tissues reflects the 
involvement of prostaglandins in a vast number of physiological processes 
(Horrorbin, 1978). Prostaglandins and thromboxanes are also intimately 
involved in the control of platelet activity, indeed Gerrard and White 
(1978) considered them to be "middlemen" modulating platelet function. 
Arachidonic acid metabolites involved in platelet function are presented in 
Figure 1.2.
1.2.7.1 Platelet-derived prostaglandins and thromboxanes
Prostaglandin involvement in platelet function was first proposed by 
Kloeze (1967; 1969) who demonstrated PGE^-induced inhibition and 
PGE2-induced enhancement of platelet aggregation. It was subsequently 
demonstrated that platelets manufactured and released PGE2 and PGF2a 
during aggregation (Smith and Willis, 1970; Silver et al. , 1972).
Although these early studies initiated a very important aspect of platelet 
research it has become apparent that PGE2 , PGF2 and PGE^ play only 
a minor role in modulating platelet activity.
More important discoveries of prostaglandin involvement in platelet 
function were initiated by the demonstration that platelets produce and 
release the prostoglandin cyclic endoperoxides PGG2 and PGH2 (Hamberg 
and Samuelsson, 1974; Hamberg et al., 1974; Smith et al., 1974); in 
addition, these were highly potent inducers of platelet aggregation. The 
enzyme responsible for the production of the cyclic endoperoxides was named 
cyclo-oxygenase. The same groups subsequently demonstrated the production, 
release and proaggregatory properties of thromboxane A2 (TXA2) which is 
a metabolite of PGH2 (Hamberg et al., 1975; Smith et al., 1976a).
TXA2 is much more potent and unstable than its precursors and is 
hydrolyzed to the non-active, stable metabolite TXB2 .
It has been demonstrated that PGG2/H2 a"d TXA2 Part mediate
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PLATELET STIMULATION
l
"ACTIVATION" OF PHOSPHOLIPASE
FREE ARACHIDONIC ACID
ENDOPEROXIDE PGH2
THROMBOXANE B2
ENDOTHELIAL
CELLS
PROSTACYCLIN
\S Y N T H E T A S E
PROSTACYCLIN PGI2
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Figure 1.2 The metabolism of arachidonic acid by platelets and endothelial 
cells
Platelet stimulation results in the liberation of arachidonic acid from 
platelet phospholipids, and is subsequently metabolized by the 
cyclo-oxygenase and lipoxygenase pathways.
Endothelial cells may produce prostacyclin from endogenous or exogenous 
(platelet-derived) arachidonic acid or cyclic endoperoxides.
HPETE, 12-hydroperoxyeicosatetraenoic acid.
HETE, 12-hydroxyeicosatetraenoic acid.
MDA, malondialdehyde.
HHT, 12-hydroxyheptadecatrienoic acid.
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the second phase of aggregation and release induced by ADP and adrenaline 
and the monophasic aggregation pattern exhibited by collagen and thrombin 
(Smith et al., 1974; Malmsten et al. , 1975). It has also been shown that 
PGG2/H2 and/or TXA2 initiate contraction and the release reaction 
(Gerrard and White, 1975; Gerrard et al., 1977; Gorman, 1979) and 
patients with platelet cyclo-oxygenase deficiency have a storage pool type 
disease as a result (Malmsten et al. , 1975).
Whether PGG2/H2 or their metabolite TXA2 bring about aggregation 
and release is a moot point resulting from conflicting reports on the 
necessity for TXA2 production from PGG2/H2 prior to platelet 
responses (Gerrard and White, 1978; Horrorbin, 1978). Elucidation of the 
possible individual roles played by these substances awaits the production 
and characterization of more specific inhibitors of thromboxane synthetase.
The mechanism of action of PGG2/H2 and TXA2 is unclear. Based 
on structural considerations and subsequent experimental findings TXA2, 
but not PGG2, has been ascribed with Ca^+ ionophoretic properties and 
if manifested in vivo may mediate the increase in cytoplasmic Ca^+ that 
is associated with platelet activation (Gerrard and White, 1978).
In addition to producing proaggregatory metabolites of arachidonic 
acid during aggregation, platelets are capable of producing inhibitory 
metabolites. PGD2 is produced during aggregation, possibly in amounts 
sufficient to inhibit aggregation (Smith et al., 1976b; Oelz et al., 1977) 
and may represent a negative feedback control mechanism.
The role played by PGE^ in the regulation of platelet function is 
conjectural. PGE^ is derived from DHGLA and is a moderately potent 
inhibitor of platelet aggregation; however, as platelet lipids contain 
little if any DHGLA (Cohen and Derksen 1969; Marcus et al. , 1969), PGE]^
has been discounted from playing a major role in platelet function (Smith 
and Silver, 1976). A more recent report shows there to be more PGE^ than 
PGE2 in unstimulated platelets and suggests that it may play a role in 
the control of basal activity. (Lagarde and Dechavanne, 1979).
It is well established that PGEj and PGD2 inhibit platelet 
aggregation by elevation of platelet cyclic AMP; however, one report 
suggests that PGE^ may also inhibit aggregation independently of platelet 
cyclic AMP production by interaction with a plasma cofactor. (Sinha and 
Colman, 1978).
In addition to the cyclo-oxygenase pathway of arachidonic acid 
metabolism, platelets possess the lipoxygenase pathway (Figure 1.1). The 
relevance of this pathway in human platelets is poorly understood, but 
evidence suggests that lipoxygenase products play important roles in 
platelet function; thus HPETE has been reported to inhibit thromboxane 
synthesis (Hammarström and Folardeau, 1977). Consistent with this finding 
is the observation that patients with decreased platelet lipoxygenase 
activity have hypersensitive platelets (Okuma and Uchino, 1977); however, 
Dutilh et al. (1979) have reported that HETE is essential for rat platelet 
aggregation; HETE also has chemotactic properties for neutrophilic 
leucocytes (Turner et al., 1975). A third lipoxygenase product 8,11,12- 
trihydroxyeicosatrienoic acid (THETE) has recently been reported to be 
formed during platelet aggregation (Bryant and Bailey, 1979).
The sources of arachidonic acid are the platelet membrane 
phospholipids; Ca^^-dependent phospholipases have been described which 
hydrolyze arachidonic acid from the 2-position of platelet phosphatidyl 
choline, ethanolamine and inositol (Schoene and Iacono, 1975; Russel and 
Deykin, 1976; Bills et al., 1977; Blackwell et al., 1977). Bell et al.
(1979) have suggested that although present, phospholipase A2 cannot
account for sufficient arachidonic acid release during thrombin 
stimulation, and phospholipase C and diglyceride lipase have been 
implicated in its liberation from phosphatidyl inositol.
1.2.7.2 Vasculature-derived prostaglandins
It has been acknowledged for many years that vascular endothelium 
presents a non-reactive surface towards platelets. Recently our 
understanding of this property has been furthered by the discovery that 
prostaglandin cyclic endoperoxides may be transformed by human vascular 
tissue into a substance with potent antiaggregatory activity. The 
substance was originally named PGX, but subsequently renamed prostacyclin 
(PGI2 ; Johnson et al., 1976; Moncada et al., 1976, 1977a). The 
discovery that vascular tissue could convert potent proaggregatory 
substances released from platelets into a potent antiaggregatory agent 
initiated a very important and fruitful era of reseach on platelet-vessel 
wall interaction in the physiology and pathology of vascular homeostasis. 
Clearly, factors which pertubate the balance of metabolites produced from 
the common precursors may result in pathological events.
The mode of action of PGI2 was clarified by demonstration that it 
was the most potent stimulator of cyclic AMP accumulation in platelets 
known at the time (Best et al., 1977; Gorman et al., 1977; Tateson et
al. , 1977). The vascular endothelial cell appears to be the most active 
producer of PGI2 (MacIntyre et al., 1978), although production by other 
vascular cell types has been reported (Baenziger et al., 1977; Moncada ejt 
al. , 1977b; Tansik et al., 1978). Endothelial cells have the ability to 
produce PGI2 both endogenously and from exogenously provided substrates 
(Weksler et al., 1977; MacIntyre et al., 1978), although the ability of 
endothelial cells to produce PGI2 from platelet-derived PGH2 has 
recently been questioned (Hornstra et al., 1979).
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The inhibition of platelet function by PGI2 is not an absolute 
phenomenon and it appears that in the presence of low levels of PGI2 
platelets lose their ability to aggregate, but are still able to adhere; 
only at higher concentrations does PGI2 inhibit adherence (Higgs et al., 
1978). These responses may allow the platelet to interact with intact 
endothelium and maintain vascular integrity without leading to thrombus 
formation.
PGI2 has been described as a "circulating hormone" produced, but not 
degraded, by the lung vasculature (Gryglewski et al., 1978; Moncada et al., 
1978). However, other groups have failed to demonstrate circulating 
PGl2-like activity (Smith et al., 1978, 1979; Haslam and McClenaghan,
1979; Steer et al. , 1980).
1.2.7.3 Inhibitors of prostaglandins and thromboxanes
Inhibitors of arachidonic acid release, metabolism and action of 
metabolites are useful tools for studying the roles of such products in 
regulating platelet function and may also have important clinical 
ramifications.
The best documented inhibitors of prostaglandin synthesis are the 
non-steroidal anti-inflammatory drugs, in particular acetylsalicylic acid 
(ASA, aspirin). These agents act by inhibiting cyclo-oxygenase, but this 
is not necessarily achieved by similar mechanisms. Aspirin inactivates 
cyclo-oxygenase by acetylation of its active site (Roth et al., 1975). As 
a result of the platelet's inability to resynthesize enzymes the aspirin 
effect is a function of platelet turnover, and under normal conditions 
lasts for seven to ten days. Aspirin also inhibits endothelial cell 
cyclo-oxygenase resulting in diminished prostacyclin production (Nordj^y e_t 
al. , 1978). However, as a result of a lesser senstivity to aspirin, and 
resynthesis of cyclo-oxygenase by the endothelial cell, the effect may be
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of a s h o r t e r  d u r a t i o n  t h a n  i n  p l a t e l e t s  ( C z e rv io n k e  e t  a l . , 1979; J a f f e  
and W e k s l e r ,  1979) .
Numerous i n h i b i t o r s  of  p r o s t a g l a n d i n  and thromboxane  p r o d u c t i o n  or 
a c t i o n  have been  d e s c r i b e d .  These may be s p e c i f i c  f o r  c y c l o - o x y g e n a s e ,  
l i p o x y g e n a s e ,  thromboxane s y n t h e t a s e  or  p r o s t a c y c l i n  s y n t h e t a s e .  Most 
a s p e c t s  of  t h e s e  have been c o v e re d  i n  a r e c e n t  r e v i e w  by G ryg lew sk i  ( 1 9 7 9 ) .
1 . 2 . 8  C y c l i c  n u c l e o t i d e s
1 . 2 . 8 . 1  C y c l i c  AMP
C y c l i c  AMP i s  produced  by t h e  enzyme a d e n y l a t e  c y c l a s e  which i s  
a s s o c i a t e d  w i t h  t h e  p l a t e l e t  membrane. The im p o r t a n c e  of  t h e  p l a t e l e t ’ s 
a b i l i t y  to  m a n u f a c t u r e  c y c l i c  AMP has  on ly  r e l a t i v e l y  r e c e n t l y  been 
e l u c i d a t e d .  Wolfe and Shulman (1969)  d e m o n s t r a t e d  t h a t  t r e a t m e n t  of  
p l a t l e t s  w i t h  PGEj r e s u l t e d  i n  s t i m u l a t i o n  of  a d e n y l a t e  c y c l a s e  and i t  
was s u b s e q u e n t l y  d e m o n s t r a t e d  t h a t  c y c l i c  AMP m e d i a t e d  t h e  i n h i b i t o r y  
e f f e c t s  of  PGEi and PGD2 on p l a t e l e t  a g g r e g a t i o n  ( B a l l  e t  a l . , 1970;
M i l l s  and Sm ith ,  1971; M i l l s  and M a c f a r l a n e ,  1974 ) .  However ,  i t  was t h e  
d i s c o v e r y  o f  p r o s t a c y c l i n  and i t s  p o t e n t  s t i m u l a t i o n  of  a d e n y l a t e  c y c l a s e  
w i t h  c o n s e q u e n t  i n h i b i t i o n  of  p l a t e l e t  a g g r e g a t i o n  t h a t  uncove red  a major  
r o l e  f o r  p l a t e l e t  a d e n y l a t e  c y c l a s e .
P l a t e l e t s  a l s o  c o n t a i n  c y c l i c  AMP p h o s p h o d i e s t e r a s e ,  a c y t o p l a s m i c  
enzyme r e s p o n s i b l e  f o r  t h e  d e g r a d a t i o n  of  c y c l i c  AMP. The b a l a n c e  be tw een  
a d e n y l a t e  c y c l a s e  and p h o s p h o d i e s t e r a s e  a c t i v i t y  d e t e r m i n e s  t h e  l e v e l  of 
c y c l i c  AMP i n  t h e  p l a t e l e t .  I n h i b i t i o n  o f  p h o s p h o d i e s t e r a s e  w i t h  
p a p a v e r i n e ,  t h e o p h y l l i n e ,  c a f f e i n e  or  d i p y r i d a m o l e  r e s u l t s  i n  the  e l e v a t i o n  
of  b a s a l  c y c l i c  AMP l e v e l s  and a l s o  augments  p r o s t a g l a n d i n - s t i m u l a t e d  
l e v e l s  (Sa lzman e t a l .  , 1972; Wang e t  a l . ,  1978) .
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Elevation of intracellular cyclic AMP is one of the most effective 
means of inhibiting all aspects of platelet aggregation and release 
suggesting that its mode of action might involve Ca^+ antagonism which is 
so intimately concerned in platelet function (Section 1.2.4). Indeed
O  Istudies on cyclic AMP-Ca interaction have demonstrated that cyclic AMP 
is involved in maintaining a low level of cytoplasmic Ca^+ by stimulation 
of the Ca^+ extrusion pump (Käser-Glanzmann et al. , 1977). Recently, 
llaslam et al. (1979) have suggested that cyclic AMP initially 
phosphorylates specific platelet proteins which in turn stimulate Ca^+ 
uptake from the cytoplasm.
Although numerous groups have demonstrated that aggregating agents 
will inhibit prostaglandin stimulation of adenylate cyclase and subsequent 
cyclic AMP accumulation the hypothesis that such agents induce aggregation 
by lowering basal levels of cyclic AMP is highly conjectural (Haslam et 
al., 1979).
1.2.8.2 Cyclic GMP
The relevance of the platelet's ability to produce cyclic guanosine 
3’,5’-monophosphate (cyclic GMP) is poorly understood. Cyclic GMP in a 
number of systems has a reciprocal relationship to cyclic AMP (The 
"Yin-Yang" hypothesis of Goldberg et al., 1975). In platelets it has been 
proposed that the increase in cyclic GMP noted during platelet activation 
may mediate aggregation and release (Chiang et al. , 1976). However, it 
appears that the increase in cyclic GMP is secondary to platelet 
aggregation i.e. an effect, rather than the cause, of aggregation (Haslam 
et al., 1978).
Despite these latter reports it is of interest to note that certain 
PUFA and their peroxides stimulate platelet guanylate cyclase ( Glass e_t 
al., 1977; Hidaka and Asano, 1977). PGG2 and PGH2 have also been
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reported to stimulate guanylate cyclase (Graff et al. , 1979). Shier et al. 
(1976) have demonstrated that lysolecithin, a possible by-product of 
arachidonic acid liberation from platelet lecithin (phosphatidyl choline), 
activates guanylate cyclase while reciprocally inhibiting adenylate 
cyclase in 3T3 fibroblasts.
1.3 PLATELETS, ATHEROSCLEROSIS, THROMBOSIS AND CORONARY HEART DISEASE
1.3.1 Coronary heart disease
Atherosclerosis and thrombosis resulting in the narrowing or occlusion 
of arterial blood vessels are considered to be important lesions underlying 
the clinical manifestations of a number of obstructive vascular diseases, 
perhaps the most common of these being coronary heart disease (CHD). 
Clinical manifestations of CHD range in severity, depending on the degree 
and location of coronary arterial occlusion, from angina pectoris through 
myocardial infarction to sudden death.
1.3.1.1 Epidemiology of CHD
CHD is a hallmark of developed societies in which it is the most 
common cause of death; indeed, it is considered by many public health 
authorities to have reached epidemic proportions.
Early clues to the causes of CHD were obtained the study of 
experimental atherosclerosis in rabbits fed a diet rich in animal products 
(Ignatowski, 1909; Anishchkow and Chalatow, 1913). Since the early days 
of research into atherosclerosis a vast amount of literature has 
accumulated on the origins of atherosclerosis and CHD, the majority of 
which has been produced in the past decade and is concerned with the 
cholesterol component. National and International epidemiological studies 
have demonstrated correlations between dietary lipid and mortality from 
CHD. Representative of these studies is the classic seven countries study
of Keys (1970) in which eighteen populations in seven countries were 
studied for a decade and correlations between various factors and CHD were 
constructed. It was found that serum cholesterol was a function of the 
percentage of dietary calories provided by saturated fat and that death 
from CHD was a function of the resulting hypercholesterolaemia.
More recently, it has been demonstrated that of the circulating 
lipoproteins, of which cholesterol and other lipids are constituents, the 
ratio of low density lipoprotein (LDL) to high density lipoprotein (HDL) 
cholesterol determines an individual’s risk of developing CHD.
CHD is multifactorial in origin and cannot be absolutely related to a 
single cause, thus, "risk factors" are used to describe conditions 
associated with the incidence of CHD. Thus, elevated LDL cholesterol is 
recognised to be a strong risk factor for CHD; in addition, there are two 
other major risk factors for CHD, i.e. cigarette smoking and hypertension. 
Other risk factors and conditions reported to be associated with CHD are 
listed below.
It is apparent from the list that not all the factors are open to
intervention.
(i) Hypercholesterolaemia (x) Menopause
(Ü) Hypertension (xi) Increasing age
(iii) Cigarette smoking (xii) Family history
(iv) Diabetes mellitus (xiii) Behavioural patterns
(v) Homocystinaemia (xiv) Sedentary lifestyle
(vi) Oral contraception (xv) Hyperuricaemia
(vii) Hypertriglyceridaemia (xvi) Occupational hazards
(viii) Obesity (xvii) Soft drinking water
(ix) Maleness (xviii) Coffee intake
There are numerous publications which review and summarize
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epidemiological studies and discuss the risk factors associated with CHD. 
The following are a few selected references: Sirtori et al., 1973;
Davidson e t a l . , 1975; Manning and Haust, 1975; Kannel, 1978; Lewis and 
Naito, 1978.
1.3.1.2 Nature of the atheromatous lesion
The fibrous or fibrolipid plaque is regarded as the archetypal lesion 
of atherosclerosis (Woolf, 1977). Characteristically, the fibrous plaque 
is a smooth, elevated, greyish white structure which varies from several 
millimetres to over one centimetre in diameter. The dense fibrous 
superficial layer can be more readily appreciated under the dissecting 
microscope. On the cut surface the deeper part of the lesion is often 
yellow because of the large amount of lipid at this site. The plaques are 
found most commonly in the abdominal aorta and the coronary arteries. The 
superficial part is made up of collagen in which there are variable numbers 
of cells which tend to be elongated; elastin fibres are scanty. On the 
luminal side of the fibrous cap there is a layer of endothelial cells and 
beneath it a disorganized mass of lipid material with cholesterol clefts; 
cellular debris is often seen. The lipid mass makes up a variable amount 
of the plaque, sometimes accounting for most of it but sometimes being 
relatively inconspicuous. With electron microscopy the cells in the 
fibrous cap show many of the features of SMC, although myofilaments are 
often sparse; lipid inclusions may be present in some of these SMC. In 
addition there are ovoid foam cells of indeterminate origin (Pearson e_t 
al. , 1977). One may also find "complicated lesions" which are further 
developed fibrous plaques in which vascularization, calcification, 
haemorrhage and necrosis have occurred.
The lipid components of the atherosclerotic lesion are predominantly 
cholesterol and cholesterol esters with some phospholipid. The lipid
components appears to be variable and dependent on the advancement of the 
lesion (Hata and Ishii, 1977). Further details and discussion of the 
atherosclerotic lesion may be found in the following reviews: Pearson et_
al. , 1977; Woolf, 1977.
1.3.2 Theoretical models of atherosclerosis 
1.3.2.1 The response to injury hypothesis
The response to injury hypothesis (Ross and Glomset, 1976) is a 
relatively recent adaption of a long standing proposal made by Virchow 
(1856) who suggested that endothelial damage initiates the atherogenic 
process. Ross and Glomset extended this concept and incorporated more 
recent modifications of Virchow’s observations proposed by Duguid (1949), 
Thomas et al. (1963), French (1966), Wissler (1974), and Mustard and 
Packham (1975). The response to injury hypothesis views atherosclerosis as 
comprising the following series of events:
(i) Vascular injury resulting in damage to, or removal 
of, endothelial cells;
(ii) Adherence, aggregation and release of platelet materials 
at the site of exposed subendothelial tissue;
(iii) Proliferation of SMC in response to platelet and plasma 
factors;
(iv) Synthesis of connective tissue and deposition of lipids in 
the intimal SMC.
Evidence for the response to injury hypothesis is convincing. It has 
been demonstrated that endothelial damage, albeit of a highly 
unphysiological manner such as balloon catheterization (Stemerman and Ross, 
1972) or aortic catheters (Bjökerud and Bonjers, 1971; Moore 1973); and 
perhaps in a more pertinent manner such as hypercholesterolaemia (Ross and 
Harker, 1976), homocystinaemia (Harker et al., 1974, 1976),
endotoxaemia (Gaynor et al. , 1970), immune mechanisms (Minick and Murphy,
1973) or hypertension (Weiner et al., 1969), is conducive to the production 
of atherosclerotic plaques.
Following focal endothelial loss, platelets are thought to adhere to 
the exposed subendothelium and release their granular contents including 
the PDGF which has been demonstrated to be essential for the modulation, 
proliferation and synthetic capacity of SMC in culture. The response to 
injury hypothesis emphasizes the role played by platelets and the PDGF in 
the in vivo intimal accumulation of SMC. LDL derived from 
hypercholesterolaemic serum also stimulates the proliferation of SMC (Ross 
and Glomset, 1973; Fischer-Dzoga and Wissler, 1976). In addition, 
diabetic serum (Ledet, 1976, 1977) or insulin (Stout et al., 1975) 
stimulate the proliferation of cultured SMC.
Thus it appears that several of the risk factors for CHD may be 
implicated in the response to injury hypothesis in terms of endothelial 
damage and SMC proliferation.
1.3.2.2 The monoclonal hypothesis
The monoclonal hypothesis of Benditt and Benditt (1973) in many 
respects is in accord with the response to injury hypothesis. The major 
difference is concerned with the stimulus responsible for the proliferation 
and accumulation of intimal SMC. The monoclonal hypothesis views the 
intimal SMC mass as a benign neoplastic-type cell line originating from a 
single cell. Evidence supporting the theory involved study of the 
isoenzyme profile of plaque cells and demonstrated that 75% of more than 
one hundred raised lesions were monotypic, whereas less than 1% of fifteen 
hundred samples of normal artery contained cells that were monotypic 
(Benditt, 1977). If the monoclonal theory is relevant to atherogenesis 
then the question of mutagen involvement arises; Benditt has discussed the
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p o s s i b i l i t y  t h a t  components  o f  c i g a r e t t e  smoke and o x i d e s  of  c h o l e s t e r o l ,  
b o th  of  which a r e  t r a n s p o r t e d  i n  t h e  l i p o p r o t e i n s ,  may be t a k e n  up by SMC 
and a c t  a s  t h e  m u ta g e n ic  s t i m u l u s  f o r  s u b s e q u e n t  p r o l i f e r a t i o n  ( B e n d i t t ,  
1977) .  Thus t h e  t h e o r y  may r e l a t e  t o  known r i s k  f a c t o r s  f o r  CHD.
1 . 3 . 2 . 3  The th rom bogen ic  t h e o r y
The th rom boge n ic  t h e o r y  o r i g i n a t e s  f rom R o k i t a n s k y  (1852)  who viewed 
a t h e r o s c l e r o s i s  a s  a d e p o s i t i o n ,  or  " e n c r u s t a t i o n "  o f  endogenuous  b lood  
components  on t h e  s u r f a c e  of  t h e  e n d o t h e l i u m .  T h i s  t h e o r y  was u p d a te d  by 
Duguid (1949)  who c o n c lu d e d  from s t u d i e s  of  a t h e r o m a t o u s  a r t e r i e s  t h a t  many 
of  t h e  l e s i o n s  were i n  f a c t  a r t e r i a l  th ro m b i  which ,  by th e  p r o c e s s  o f  
o r g a n i z a t i o n ,  had been  c o n v e r t e d  i n t o  f i b r o u s  t h i c k e n i n g s .  He a l s o  
r e p o r t e d  t h a t  t h e  o r g a n i z i n g  th rombus may be c o v e re d  i n  e n d o t h e l i u m  and 
c o u ld  unde rgo  f a t t y  c h a n g e s .
C u r r e n t  f e e l i n g s  on t h e  th rom bogen ic  t h e o r y  a r e  t h a t  th rom bi  may be 
i n c o r p o r a t e d  i n t o  u n d e r l y i n g  l e s i o n s ,  b u t  p r o o f  of  t h ro m b i  i n i t i a t i n g  
a t h e r o m a t o u s  l e s i o n s  i s  l a c k i n g .
1 . 3 . 2 . 4  Other  t h e o r i e s
T h e o r i e s  such as  t h e  c l o n a l - s e n e c e n c e  model  ( M a r t i n  and S p r a g u e ,  1973) 
and t h e  f i b r i n  h y p o t h e s e s  ( C o p le y ,  1979; K a d i s h ,  1979) have  been  p r o p o s e d ,  
bu t  t h e i r  r o l e s  i n  t h e  i n i t i a t i o n  and deve lopm en t  of  a t h e r o s c l e r o s i s  
r e q u i r e  f u r t h e r  i n v e s t i g a t i o n .
1 . 3 . 3  P l a t e l e t  i n v o lv e m e n t  i n  CHD
There  i s  s u b s t a n t i a l  e v i d e n c e  t h a t  p l a t e l e t s  a r e  i n v o l v e d  i n  b o t h  t h e  
i n i t i a t i o n  and p r o g r e s s i o n  of  a t h e r o s c l e r o s i s  and t h r o m b o s i s .  As s u c h ,  
p l a t e l e t s  may be an a p p r o p r i a t e  t a r g e t  f o r  t h e  p r e v e n t i o n  and t r e a t m e n t  of
CHD.
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1 . 3 . 3 . 1  P l a t e l e t s  i n  t h e  p a t h o g e n e s i s  of  a t h e r o s c l e r o s i s
P l a t e l e t s  a r e  t h o u g h t  to  be i n v o lv e d  i n  t h r e e  i m p o r t a n t  a s p e c t s  of  
a t h e r o s c l e r o s i s ,  v i z .  e n d o t h e l i a l  damage, SMC p r o l i f e r a t i o n  and p l a q u e  
d e v e l o p m e n t .
There  a r e  i n d i c a t i o n s  t h a t  p l a t e l e t s  m e d i a t e  e n d o t h e l i a l  damage 
a l t h o u g h  t h e s e  r e p o r t s  a r e  o f  a p r e l i m i n a r y  n a t u r e  and t h e  mechanisms 
i n v o l v e d  r e q u i r e  e l u c i d a t i o n .  Lough and Moore (1972 ,  1975) r e p o r t e d  t h a t  
t h r o m b in ,  t h rom bi  or  p l a t e l e t - f i b r i n  a g g r e g a t e s  were c a p a b l e  of  i n d u c i n g  
e n d o t h e l i a l  damage; J o r g e n s e n  e t  a l . ( 1970)  r e p o r t e d  v a s c u l a r  damage 
s e c o n d a r y  to  p l a t e l e t - f i b r i n  a g g r e g a t e  f o r m a t i o n  a f t e r  i n f u s i o n  o f  ADP i n t o  
c o r o n a r y  a r t e r i e s  of  e x p e r i m e n t a l  a n i m a l s .  The same g roup  have a l s o  
d e s c r i b e d  s p o n t a n e o u s l y  o c c u r i n g  l e s i o n s  o f  a o r t i c  e n d o t h e l i u m  r e l a t e d  t o  
t h e  a t t a c h m e n t  of  p l a t e l e t s  or  p l a t e l e t  a g g r e g a t e s  to  t h e  e n d o th e l iu m  
( J o r g e n s e n  e t  a l . ,  1973) .  Mus ta rd  and Packham (1970)  d e m o n s t r a t e d  t h a t  
damage to  t h e  m i c r o c i r c u l a t i o n  i n  r e s p o n s e  to  a n t i g e n - a n t i b o d y  complexes  
was due to  p l a t e l e t  a g g r e g a t i o n  and r e l e a s e .
P l a t e l e t  i n v o lv e m e n t  i n  SMC p r o l i f e r a t i o n  and th e  p o s s i b l e  
c o n t r i b u t i o n  of  th rom bi  to  p l a q u e  deve lo pm en t  have been d i s c u s s e d  e a r l i e r .
F u r t h e r  e v id e n c e  f o r  p l a t e l e t  i n v o lv e m e n t  i n  a t h e r o g e n e s i s  h a s  been 
p r o v id e d  by t h e  u se  of  a n t i p l a t e l e t  a g e n t s  i n  e x p e r i m e n t a l  a t h e r o s c l e r o s i s .  
D ip y r id a m o le  has  p roved  e f f e c t i v e  i n  c o r r e c t i n g  p l a t e l e t  s u r v i v a l  and 
p r e v e n t i n g  SMC p r o l i f e r a t i o n  i n  h o m o c y s t in e -  or d i e t a r y - i n d u c e d  
a t h e r o s c l e r o s i s  (Harker  e t  a l . ,  1976; Ross and H a r k e r ,  1976) .  S i m i l a r l y ,  
i t  has  been d e m o n s t r a t e d  t h a t  t h e  von W i l l e b r a n d  p i g  i s  n o t  a s  s u s c e p t i b l e  
t o  s p o n ta n e o u s  or  d i e t a r y - i n d u c e d  a t h e r o s c l e r o s i s  a s  i t s  normal  c o u n t e r p a r t  
( F u s t e r  e t  a l . ,  1978) .  T hrom bocy topaen ia  has  been e f f e c t i v e  i n  r e d u c i n g  or  
p r e v e n t i n g  SMC p r o l i f e r a t i o n  i n  a n im a ls  w i t h  c h r o n i c  i n d w e l l i n g  c a t h e t e r s  
or  a f t e r  i n t r a - a r t e r i a l  b a l l o o n  c a t h e t e r i z a t i o n  (F r iedman  e t  a l . ,  1976;
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Moore et al., 1976)
1.3.3.2 Platelet function and risk factors
If the platelet does indeed mediate any of the stages of plaque 
development one might expect to find altered platelet function associated 
with at least some of the risk factors for CHD; generally this association 
has been demonstrated. Although the effects of all the risk factors, 
either alone or in combination, have not been investigated one of the major 
risk factors for CHD, hypercholesterolaemia, has been studied in some 
detail. Such studies have demonstrated increased platelet activity 
associated with hypercholesterolaemia in terms of PF3 activity and 
availability (Nord^y and R^dset, 1971a; Carvalho et al., 1974; Shattil 
et al., 1977), and sensitivity to aggregating agents and subsequent release 
of adenine nucleotides (Carvalho et al., 1974). Examination of the 
literature does reveal some discrepancies in findings; for example Joist 
et al. (1979) could not confirm the above findings related to aggregation
studies, but did demonstrate increased PF3 activity and availability, 
shorter template bleeding times, and increased plasma levels of antiheparin 
activity in hyperlipidaemic subjects. Disagreement in findings may result 
from varying degrees of morbidity and the experimental techniques employed.
In addition to hyperlipidaemic risk factors, other risk factors have 
been associated with altered platelet function, namely: family history
(Murphy and Mustard, 1962; Hampton and Gorlin, 1972); cigarette smoking 
(McVerry and Levine, 1976; Bierenbaum et al., 1978); stress (Haft, 1976) 
and diabetes mellitus (Bern, 1978).
Finally, it must be stressed that in any discussion of platelet 
hyperactivity associated with risk factors one must take into account the 
possibility of platelet activation secondary to pre-existing
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atherosclerotic lesions. This factor highlights the usefulness of 
experiments in which risk factors are investigated in healthy experimental 
subjects in an attempt to elucidate cause or effect relationships.
1.3.3.3 Antiplatelet agents in the control of atherosclerosis and 
thrombosis
A great number of agents have been demonstrated to have antiplatelet 
properties in vitro and a number have been effective in reducing 
experimentally-induced atherosclerosis and thrombosis in animals. However, 
clinical trials of antiplatelet agents have on the whole been 
disappointing, perhaps with the exception of the Anturane Reinfarction 
Trial (1978) and the Canadian Cooperative Study (1978).
Meanwhile, the search for safe and effective antiplatelet agents 
continues.
1.4 SUMMARY
A brief description of the historical aspects of research into platelet 
function has been presented and it is apparent that as early as 1882 
platelets were described as adhering to areas of damaged endothelium 
resulting in the formation of thrombi, suggesting both physiological and 
pathological roles for platelets. However, it is a result of research 
conducted in the past twenty years that we now have a detailed, but by no 
means complete, comprehension of platelet function.
The ultrastructure and composition of the platelet have been described 
in detail and in turn these observations have been related to the 
physiological and pathological roles played by the platelet. Factors 
involved in the modulation of platelet activity have also been described; 
clearly, knowledge of such factors is fundamental to our understanding of 
platelet activities. Probably the most important area of research that has
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evolved in the past decade is the role played by arachidonic acid 
metabolites in controlling platelet activity and these have been given 
comprehensive coverage in the introductory chapter.
The latter sections of the introductory chapter have dealt with 
interrelationships between platelets and obstructive vascular disease, 
particularly CHD, deaths from which have reached epidemic proportions in 
developed societies. Current concepts of CHD implicate the platelet in 
both the initiation and development of atherosclerosis which is a major 
contributory factor to CHD.
There is some evidence to suggest that "hyperactive" platelets may 
mediate endothelial damage and SMC proliferation which are major components 
of atherogenesis. Thus, research into factors which are conducive to the 
production, or prevention, of the activation of platelets may be of great 
importance to the public health of developed societies.
1.5 AIMS OF THE PROJECT
From the foregoing discussion it is clear that there is a strong case 
for platelets being involved in atherogenesis, and there is some supportive 
evidence that this process may be accelerated if the platelets are in a 
more active state. Atherosclerosis is the lesion underlying CHD, and of 
the numerous risk factors implicated in atherosclerosis and CHD, the lipid 
component is one of the most widely investigated and commands major 
recommendations by public health authorities of a number of developed 
societies. The recommendations stress the pathological consequences of 
elevated serum lipids, and advocate a decrease in the total fat intake 
while increasing the relative proportions of unsaturated to saturated fats 
in the diet.
In view of these facts it is essential to understand the effects of
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both risk factors for CHD, and factors reported to reduce the incidence of 
CHD, on human platelet and vessel wall function. Such research may 
validate existing recommendations and also lead to more effective 
preventive measures with the aim of reducing the incidence of CHD and other 
obstructive vascular diseases.
Thus, the thrust of this project has been an investigation of the 
effects of a number of factors, which have been implicated in either 
promoting or reducing atherosclerosis, on human platelet and vessel wall 
function. These included:
(i) The effect of saturated or polyunsaturated fat diets on human 
platelet composition and function;
(ii) The effect of hypercholesterolaemia on platelet composition and 
cyclic AMP status;
(iii) The effect of EPA on human platelet function and endothelial cell 
behaviour.
In addition emphasis has been placed on the selection and development 
of techniques that:
(i) Reflect in vivo phenomena;
(ii) Have not been applied to such studies previously;
(iii) May locate the site(s) of action of various factors investigated.
CHAPTER 2
MATERIALS AND METHODS
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2.1 METHODS
Procedures for the collection of blood and the subsequent preparation 
and handling of either platelet-rich plasma (PRP) or platelet-poor plasma 
(PPP) are critical. Unless these procedures are carefully performed in a 
standardized manner, inconsistent and artefactual data may result. The 
necessity for standardization is exemplified in subsequent chapters.
All platelet function studies were performed on human platelets.
Blood was collected via a 21 gauge butterfly cannula with a 12 inch 
extension tube. Venepuncture was performed on the most easily accessible 
antecubital vein utilizing venous stasis. An absolute criterion for blood 
collection‘was an atraumatic venepuncture. After blood flow through the 
tubing was apparent the venous pressure was released, the first few ml of 
blood discarded and the collection performed. The use of a butterfly 
cannula facilitated venepuncture and obviated local venous trauma when 
changing syringes.
Blood collection and platelet function studies were performed on the 
understanding that subjects had not ingested any medications known to 
influence platelet behaviour for two weeks prior to donation.
2.1.1 Platelet function studies
2.1.1.1 Citrated platelet-rich and platelet-poor plasma
Nine vol of blood were collected into 1 vol of citrate (0.1 M 
trisodium citrate, pH 7.4). PRP was prepared by centrifugation at 100 g 
for 15 min and was stored free of air in stoppered syrings at 37°C and used 
within 3 h of blood collection. After harvesting the upper platelet-rich 
fraction, PPP was prepared by centrifugation of the remaining fraction at 
1400 g for 15 min. For clotting tests and RIA, the upper 2/3 of the plasma
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fraction was further centrifuged at 8000 g (Eppendorf Microcentrifuge 3200; 
Eppendorf Instruments Ltd., Hamburg, W. Germany) for 5 min and the upper 
2/3 retained. PPP prepared in this manner had a platelet count < 1000/p 1.
2.1.1.2 ETP and CTP platelet-poor plasma
PPP was also prepared from 9 ml blood collected directly into a 
syringe containing 1 ml of ice-cold anticoagulants: ETP (EDTA, 3.3%;
theophylline, 10 mM; PGE^, 1 pg/ml) or CTP (trisodium citrate, 0.1 M; 
theophylline, 10 mM; PGE^, 1 pg/ml). The anticoagulants were prepared 
daily by the addition of PGEj to a stock solution of EDTA or citrate, and 
theophylline; all stock components were stored at -20°C. After blood 
collect ion,the stoppered syringe was placed in ice and PPP was prepared 
within 15 min by centrifugation at 8000 g for 5 min. The upper 1/3 of the 
PPP fraction was carefully removed, recentrifuged as before and the upper 
1/2 of the PPP removed and stored at -20°C. Preparation of PPP in this 
manner is a modification of the method of Ludlam and Cash (1976) and 
minimizes the release of platelet constituents in vitro and may reflect 
"circulating" plasma levels of factors released from platelets.
2.1.1.3 Platelet washing
PRP was prepared as described earlier from blood collected into 5.6 
vol of acid-citrate-dextrose (ACD; Aster and Jandl, 1964). Platelets were 
sedimented from ACD PRP at 1400 g for 15 min and after removal of PPP the 
sedimented platelets were resuspended in washing fluid (37°C) to remove 
plasma. The washed platelets were sedimented at 1400 g for 10 min and 
subsequently resuspended at 37°C in resuspending fluid. Washing and 
resuspending fluids were modified Tyrode’s buffer (Section 2.2.1).
2.1.1.4 Platelet aggregation and secretion
Platelet aggregation was determined by the turbidometric method of
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Born (1962) as modified by Mustard et al. (1964) using a Payton Dual 
Channel Aggregation Module (Payton Associates Ltd., Scarborough, Ontario, 
Canada).
Simultaneous platelet aggregation and secretion were measured in a 
Model 400 Lumi-Aggregometer (Chrono-Log Corp., Havertown, Pa., U.S.A.).
The lumi-aggregometer measures aggregation turbidometrically and the 
release of ATP by firefly-luciferase luminescence; full details have been 
published elsewhere (Feinman et al., 1977).
2.1.1.5 Platelet adherence to collagen
The adherence of platelets to collagen was assessed by the method of 
Mant (1977) which utilizes the % decrease in the platelet count of EDTA 
(0.2%) anticoagulated PRP after stirring with collagen fibres (2 pg/ml) 
over a time course of 1-6 min at 37°C.
2.1.1.6 Circulating platelet aggregates
The platelet aggregate content of circulating blood was determined by 
the method of Gjesdal et al. (1976) with the following modifications: 2 ml
of blood was collected directly into 8 ml of either solution A (0.14 M 
NaCl, 0.01 M K2HPO4, 0.11 M EDTA, 2.5% (v/v) formalin, pH 7.4), or 
solution B (0.35 M NaCl, 0.11 M EDTA, pH 7.4). Emphasis was placed on the 
need for precise sampling volumes, with the exclusion of air, during blood 
collection; if air was admitted, the sample was discarded and collection 
repeated. The 10 ml mixture was immediately transferred to a 10 ml 
polypropylene centrifuge tube, capped and gently mixed. The mixing 
procedure was repeated after 15 min standing just prior to centrifugation 
(150 g for 5 min). A sample from the middle layer of the supernatant PRP 
was diluted 1:300 and the platelet count determined. The aggregate content 
was expressed as the platelet count ratio (PCR) as described by Wu and Hoak
45
(1974). A decrease in the PCR reflects an increase in platelet aggregates.
2.1.1.7 MDA production by platelets
MDA production by platelets was measured by adding 100 pi of acetic 
acid-soluble collagen (100 pg/ml) to 1.5 ml of stirred PRP at 37°C; after 
4 min the reaction was terminated and the platelets were disrupted by the 
addition of 100 pi of a 100% solution (w/v) of trichloroacetic acid (TCA) 
in 0.1 M HC1. The precipitate was removed by centrifugation (8000 g for 6 
min) and the MDA content determined spectrophotometrically at 532 nm by the 
thiobarbiturate reaction as described by Davies et al. (1976). The stock 
MDA solution was prepared by hydrolysis of malonaldehyde tetramethylacetal 
(Eastman Kodak Co., Rochester, N.Y., U.S.A.) as described by Smith et al. 
(1976c). All MDA assays were performed in duplicate and results calculated 
from the mean.
2.1.1.8 Platelet cyclic AMP
The cyclic AMP content of washed human platelet suspensions was 
assessed by adding 1 ml of the platelet suspension (before and after 
treatment with prostaglandin solutions) to 200 pi of ice-cold TCA (30% w/v 
in 0.1 M HC1). After mixing, the precipitate was sedimented (8000 g for 10 
min) and the solution transferred to a 10 ml polypropylene tube containing 
500 pi of 1 M HC1. TCA was removed by extracting 5 times with 5 vol of 
water-saturated diethyl ether. The lower TCA-free aqueous phase was 
lyophilized overnight and subsequently assayed for cyclic AMP using kits 
(The Radiochemical Centre, Amersham, Bucks., England) based on the 
competitive protein binding method of Gilman (1970). Samples were counted 
in 10 ml of a liquid scintillant mixture (Bray, 1960) on a Packard Tri-Carb 
Liquid Scintillation Spectrometer (Packard Instrument Co. Inc., Downers 
Grove, 111., U.S.A.). All cyclic AMP assays were performed in duplicate 
and results calculated from the mean. Recovery of cyclic AMP was assessed
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by adding cyclic AMP standards to washed platelet suspensions prior to TCA 
precipitation. Mean recovery was 90.4% (± 9.7%).
2.1.1.9 Platelet-specific proteins
The platelet-specific proteins PF4 and ß-TG were determined by a 
standard double antibody RIA as described by Chesterman et al. (1978).
Antibodies used were rabbit anti-PF^ or anti-ß-TG antiserum and goat 
anti-rabbit-y-globulin antiserum. Purified PF4 and ß-TG were prepared 
from the supernatant plasma of outdated platelets as described by Morgan 
et al. (1977).
2.1.1.10 Blood cell counts
Platelet counts in PRP and PPP were performed on a Model ZF Coulter 
Counter with a 70 p orifice tube (Coulter Electronics, Harpenden, Herts., 
England). Plasma samples were diluted with Isoton (Coulter Electronics) 
and counted within 30 min of dilution. Dilutions were as follows: PRP and
washed platelet suspensions, 1:3000; PPP and PCR samples, 1:300.
Whole blood cell counts were determined on blood collected into 
standard EDTA tubes. Cell counts were performed on an automatic blood cell 
counter (Hemolog-8; Technicon Ltd., North Ryde, N.S.W., Australia)
2.1.2 Clotting assays
Clotting assays were performed using a Fibrometer (BBL, Cockeysville, 
Md., U.S.A.) with a final clotting assay volume of 400 pi at 37°C. All 
assays were performed in duplicate and results calculated from the mean.
2.1.2.1 The heparin-thrombin clotting time (HTCT)
The HTCT was used as a measure of plasma HNA; heparin is incubated 
with PPP and subsequent clotting, induced by the addition of thrombin, was
a function of the amount of heparin neutralized. The HTCT of citrated and 
CTP PPP were determined as described by Levine et al. (1977), with the 
following modifications: heparin was added at a concentration of 0.56 U/ml 
in 0.15 M NaCl and thrombin was added at approximately 10 U/ml in 0.08 M 
CaCl2 * The thrombin concentration occasionally required slight 
adjustment to maintain a daily control HTCT of between 45-55 sec. Control 
citrated PPP was PPP pooled from 6 healthy, fasted individuals, and was 
stored at -20°C. The HTCT was expressed as a % of the HTCT value of 
control PPP. In addition the HTCT was performed on citrated PPP to which 
exogenous PF^ had been added. Purified PF^ was stored as a stock 
solution of 1 Pg/ml in 0.5 M NaCl at -20°C. Appropriate dilutions were 
made with 0.15 M NaCl to obtain the range of concentrations required.
2.1.2.2 Factor Xa inhibitory activity
Factor Xa inhibitory activity of citrated PPP was determined by a two 
stage assay in which diluted test plasma was incubated with a standard Xa 
solution. Residual Xa was then assayed by its ability to clot factor X 
deficient substrate plasma. The assay has been described in detail by 
Biggs et al. (1970) and the following modifications were incorporated: 
defibrination at 56°C was omitted (Wessler et al.,1976), prior to assay 
test plasma was diluted 1 in 10 with 0.15 M NaCl. Factor Xa was used as a 
stock solution of 0.25 U/ml. The first stage incubation time employed was 
40 min.
2.1.3 Lipid studies
All solvents used were of analytical grade (Ajax Chemicals Ltd., 
Sydney, Australia). Extraction solvents contained the antioxidant 
butylated hydroxytoluene (BHT; Sigma Chemical Co., St Louis, Mo., U.S.A.) 
at 50 mg/1. Solvents used for thin-layer chromatography (TLC) contained 
BHT at 500 mg/1. If storage of purified lipids was required they were kept
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under N2 in darkness at -20°C.
2.1.3.1 Platelet lipids
The total lipid from 1 ml of washed platelet suspensions (1-5 x 
lO^/ml) was extracted into chloroform-methanol (2:1, 15 vol) and washed 
with 0.1 M KC1 (Folch et al., 1957).
(i) Total cholesterol content of the lipid extracts was determined by 
the method of Zlatkis et al. (1953) as modified by Owens and Hughes (1970). 
Total phospholipids were determined by the method of Bartlett (1959). 
Reference standards were obtained from Supelco Inc. (Bellefonte, Pa., 
U.S.A.). All cholesterol and phospholipid determinations were performed in 
duplicate and results calculated from the mean.
(ii) Platelet phospholipid fatty acid patterns were determined by a 
slight modification of the method of Nord^y and Lund (1968). TLC was 
performed on silica gel HR (Merck, Darmstadt, W. Germany) at a thickness of 
0.2 mm. The separate phospholipids were visualized by spraying with a 0.1% 
solution of 2,7-dichlorofluorescein (Sigma Chemical Co.) in 95% methanol. 
Methyl esters and dimethylacetals were prepared under N2 in 2 ml of 7%
(w/v) boron trifluoride in methanol (BDH Chemicals Ltd., Poole, Dorset, 
England) utilizing the principles of Morrison and Smith (1964). The 
methylated products were extracted by addition of hexane (4 ml) and H2O
(2 ml); after centrifugation (1000 g for 10 min) the upper hexane layer 
was collected and analysed by gas-liquid chromatography (GLC). GLC was 
performed on a Packard 7400 Series Chromatography System (Packard 
Instrument Co.) equipped with a hydrogen-flame detector. The glass column 
(180 cm x 4 mm i.d.) was packed with 10% DEGS-PS on 80/100 mesh Supelcoport 
(Supelco Inc.) and maintained at 180°C. Injection and detection ports were 
maintained at 200°C. Gas flow rates were as follows: N2 , 20 ml/min;
H2 , 20 ml/min; and air, 200 ml/min, with a column pressure of 20 p.s.i.g 
at the injection port. Methyl esters were identified by comparison with
Standards (Supelco Inc.) and quantified using retention times and peak 
heights.
2.1.3.2 Plasma and serum lipids
(i) Total serum cholesterol and triglyceride were assayed by an 
autoanalyser (Technicon Ltd.); cholesterol by the Liebermann-Burchard 
reaction as described by Ness et al. (1964) and triglyceride by the 
enzymatic method of Bucolo and David (1973).
(ii) HDL cholesterol and triglyceride were determined after 
precipitation of very low density lipoprotein (VLDL), and LDL from plasma 
with phosphotungstic acid/MgCl2 (Burstein et al., 1970). VLDL were 
isolated at density (d) < 1.006 g/ml in the preparative ultracentrifuge. 
LDL lipids were calculated as the difference between concentrations in the 
d > 1.006 fraction and the directly estimated HDL values.
2.2 MATERIALS
Materials, with the exception of those described fully in the previous 
section, were obtained, prepared, stored and used in the following manner.
2.2.1 Buffers
Washing and resuspending fluids used for platelet washing and as 
reagent diluent, in which all aggregating agents were dissolved unless 
otherwise stated, were modified Tyrode's buffer (Huzoor-Akbar and Ardlie, 
1978). Full compositional data are given in Table 2.1. Fresh solutions 
were prepared daily from refrigerated stock solutions; glucose and albumin 
(fraction V from bovine plasma, Armour Pharmaceutical Co. Ltd., Eastbourne, 
England) were added to the solution just prior to use. Apyrase (ATP 
diphosphohydrolase) was prepared from potatoes by the method of Molnar and 
Lorand (1961), and dialyzed against 0.15 M NaCl, or obtained commercially
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(Sigma Chemical Co.) and was stored at -20°C.
Citrate-albumin-glyoxaline buffer, pH 7.3, was prepared from 0.5 
parts of 20% (w/v) albumin, 15 parts of 3.8% (w/v) trisodium citrate and 75 
parts of imidazole (glyoxaline) buffer (Biggs, 1972).
2.2.2 Aggregating agents
Working solutions of aggregating agents were prepared daily from 
frozen stock solutions and kept on ice during use. Except where indicated 
aggregating agents were added at 0.1 vol of the platelet suspension to give 
the final concentration shown.
Adrenaline bitartrate (Calbiochem, San Diego, Ca., U.S.A.) and ADP 
(Sigma Chemical Co.,) were stored at -20°C in reagent diluent at a 
concentration of 10“  ^M and used within one month of preparation.
Bovine thrombin (Parke Davis and Co., Detroit, Mi., U.S.A.) was stored 
at -20°C in reagent diluent at a concentration of 1000 U/ml.
Collagen (bovine achilles tendon, Sigma Chemical Co.) was prepared as 
a suspension in acetic acid as described by Cazenave et al. (1973). The 
stock suspension containing approximately 1 mg/ml was stored at 4°C and 
diluted in reagent diluent for use.
A23187 (a kind gift from Eli Lilly Research Laboratories,
Indianopolis, Ind., U.S.A.) was dissolved in dimethylsulphoxide (DMS0; 
Mallinckrodt Inc., St Louis, Mo., U.S.A.) and stored as a stock solution of 
0.5 mg/ml at -20°C. A23187 was used at room temperature and the final
concentration of DMSO in plasma did not exceed 1%.
Arachidonic acid (99% pure; Sigma Chemical Co.) was used as the 
potassium salt (Schrör e t a l. , 1978) and was stored in the dark at -20°C
under N2» In some experiments arachidonic acid was used as the free acid
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d i s s o l v e d  i n  DMSO a t  33 mg/ml;  t h e  f i n a l  c o n c e n t r a t i o n  of  DMSO i n  plasma 
d id  n o t  e xceed  1%.
The p r o s t a g l a n d i n  c y c l i c  e n d o p e ro x id e  a n a lo g u e  ( 1 5 S ) - h y d r o x y - l l a , 
9 a - ( e p o x y m e t h a n o ) p r o s t a - 5 Z , 1 3 E - d ie n o i c  a c i d  (U46619) was a k in d  g i f t  from 
John  P ike  (The Upjohn Co . ,  Kalamazoo,  M i . ,  U . S . A . ) .  U46619 was s t o r e d  a t  
-20°C i n  t h e  d a rk  a t  a c o n c e n t r a t i o n  of  350 pg/ml i n  e t h a n o l  and d i l u t e d  i n  
r e a g e n t  d i l u e n t  b e f o r e  u s e .
2 . 2 . 3  Agents  used i n  c l o t t i n g  a s s a y s
Thrombin (P a rk e  Davis  and Co .)  was p r e p a r e d  a s  a s t o c k  s o l u t i o n  of  
1000 U/ml i n  0 .0 8  M CaCl2  and s t o r e d  a t  -20°C ;  p r i o r  to  use  i t  was 
d i l u t e d  w i t h  i c e - c o l d  0 .0 8  M CaCl2  and s t o r e d  on i c e .
Hepar in -N a  (mucous,  Commonwealth Serum L a b o r a t o r i e s ,  M e lbourne ,  V i c . ,  
A u s t r a l i a )  was p r e p a r e d  a s  a s t o c k  s o l u t i o n  of  5 U/ml i n  0 .1 5  M NaCl and 
k e p t  a t  -20°C;  p r i o r  t o  u se  i t  was d i l u t e d  w i t h  i c e - c o l d  0 .1 5  M NaCl and 
s t o r e d  on i c e .
F a c t o r  Xa (Sigma Chemica l  Co .)  was p r e p a r e d  d a i l y  a s  a s o l u t i o n  of  
0 .2 5  U/ml i n  c i t r a t e - a l b u m i n - g l y o x a l i n e  b u f f e r  and s t o r e d  on i c e .
P l a t e l e t  s u b s t i t u t e  ( D i a g n o s t i c  R eagen ts  L t d . ,  Thame, Oxon, E ng la nd )  
was p r e p a r e d  f r e s h  d a i l y  a s  a 1 :100  d i l u t i o n  i n  0 .1 5  M NaCl and k e p t  on 
i c e .
F a c t o r  X d e f i c i e n t  s u b s t r a t e  plasma ( D i a g n o s t i c  R eagen ts  L t d . )  was 
r e c o n s t i t u t e d  d a i l y  by a d d i t i o n  of  3 ml of  i c e - c o l d  d i s t i l l e d  w a te r  and
s t o r e d  on i c e .
2.2.A Miscellaneous
2.2.4.1 Aspirin
Aspirin (Ajax Chemical Co., Sydney, N.S.W., Australia) was prepared as 
a 50 mM solution in reagent diluent, pH 7.4, on the day of use and stored 
on ice.
2.2.4.2 Eicosapentaenoic acid
5,8,11,14,17-eicosapentaenoic acid (Accurate Chemical and Scientific 
Corp., Hicksville, N.Y., U.S.A.) was prepared, stored and used as the 
potassium salt (see arachidonic acid, Section 2.2.2). Upon GLC, 
eicosapentaenoic acid was found to be 93% pure (< 1% DHGLA, 2% arachidonic 
acid and 5% unidentified).
2.2.4.3 Prostaglandins
Prostaglandins used in platelet cyclic AMP studies (PGE^, PGD2 and 
PGI2 ) were a kind gift from Dr John Pike (The Upjohn Co.) and were stored 
at -20°C. During usage they were stored as stock solutions of 1 mg/ml in 
ethanol at -20°C. Working solutions were prepared in ice-cold reagent 
diluent, stored on ice and used within 1-5 min of dilution.
Other methods are detailed in respective chapters.
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CHAPTER 3
THE EFFECTS OF A DIET ENRICHED IN SATURATED OR POLYUNSATURATED 
FAT ON HUMAN PLATELET FUNCTION AND COMPOSITION
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3.1 INTRODUCTION
Several previous studies have suggested that haemostatic function in 
man and animals may be altered by manipulation of the amount and type of 
dietary fat.
One of the earliest human studies which examined the effects of 
dietary fat manipulation on platelet function was performed by McDonald and 
Edgill (1958) who demonstrated decreased platelet "stickiness" after 
feeding a low-fat diet to patients with ischaemic heart disease. More 
recently Iacono et al. (1974), in a cross-over study, reported decreased 
sensitivity to thrombin- and collagen-induced aggregation of human 
platelets after reduction of dietary fat calories from 35% to 25%.
Mustard and Murphy (1962) demonstrated that partial replacement of 
animal fat by equal quantities of vegetable fat diminished platelet 
turnover and lengthened platelet survival time. Since these early studies 
of Mustard and Murphy numerous investigations, employing a range of 
techniques, have demonstrated that dietary polyunsaturated fats (PUF) are 
conducive to decreased human platelet function, whereas saturated fats (SF) 
have the opposite effect.
Nordf^ y and R^dset (1971b) reported decreased PF3 activity of PRP 
after feeding PUF, but they observed no significant changes in platelet 
sensitivity to aggregation induced by collagen, ADP or thrombin. It was 
also shown that the quality of dietary fats was reflected in platelet 
phoshpolipid fatty acid patterns.
More recently, the filtragometer has been utilized in assessing the 
effect of dietary fats on human platelet function. This device measures 
platelet aggregation and deaggregation in flowing blood and is therefore 
thought to give a more precise index of in vivo platelet function. Using
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this method Hornstra et al. (1973) found profoundly diminished platelet 
activity after PUF feeding. These results were confirmed by Fleischman 
(1975a, 1975b) who suggested that the PUFA linoleic acid was responsible 
for the lengthening of the aggregation time and shortening of the 
deaggregation time. Although O'Brien et al. (1976a) could not confirm 
these results using the filtragometer, he did demonstrate diminished 
platelet function by several alternative techniques after replacement of 
dietary SF with PUF.
Animal experiments have also added weight to the accumulated evidence 
that dietary SF and/or cholesterol lead to enhanced platelet activity, 
thrombus formation and atherosclerosis, relative to diets with a lower 
cholesterol content and higher P/S ratio (Mustard et al., 1963; Nord^y, 
1965; Nord^y et al., 1968; Farbiszewski et al., 1969; Renaud et al., 
1970; Hornstra and Lussenburg, 1975; Joist et al., 1976b; McGregor and 
Renaud, 1977, 1978; Agradi et al., 1978).
In view of these observations and recommendations by public health 
bodies of a number of developed societies advising a decrease in total fat 
intake and an increase in the relative proportions of PUF to SF it appeared 
relevant to re-examine the effects of dietary fat modification on platelet 
function. Atherosclerosis and thrombosis are pathological features of 
obstructive vascular disease and there is evidence that platelets play a 
key role in their development (Section 1.3.3.1).
Techniques selected included those thought to be more precise 
indicators of in vivo platelet reactivity of those available and which 
might possibly locate the site(s) at which dietary fats exert their 
influence on platelet reactivity.
After enrichment of the diet of twelve volunteers with SF or PUF the 
following parameters were measured: "circulating" platelet aggregates by
the PCR; the HTCT of citrated PPP as an indication of released PF4 which 
has HNA; PF4 was also measured by a specific RIA of citrated PPP; in
addition, PF4 and (3-TG were measured RIA of ETP PPP which is thought to 
indicate their circulating levels; the production of MDA by 
collagen-stimulated platelets was used as an indication of platelet 
prostaglandin synthesis; platelet phospholipid fatty acids were determined 
to assess the effects of dietary fatty acid type on platelet lipid 
profiles; factor Xa inhibitory activity of citrated PPP was also examined. 
Platlelet counts in PRP and whole blood, and serum cholesterol and 
triglyceride levels were measured. In addition technical aspects of the 
HTCT were investigated.
3.2 MATERIALS AND METHODS
3.2.1 Subjects
Twelve university students aged 18-28 years (mean 21.3 years) were 
selected by interview to take part in the study. They were healthy, 
non-smoking males who had not taken medications for at least two weeks 
prior to the experimental period. Medications, alcohol and strenuous 
exercise were also discouraged during the study period. A dietary history 
obtained by a dietitian indicated no prior food fads and a diet 
predominantly saturated in terms of dietary fat. The subjects consumed all 
meals on an in-patient basis, but were allowed to continue their normal 
daily activities. They were, however, required to stay overnight in 
hospital to allow early morning, fasting (12 h) blood samples to be taken. 
Signed consent was obtained from each individual prior to commencement of 
the study.
3.2.2 Diet
The subjects were fed two diets, which were quantitatively identical
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in the proportions of major nutrients (approximately 45% carbohydrate, 40% 
fat and 15% protein), composed of normal Australian foodstuffs available 
from the hospital catering service. Total calories were adjusted to 
maintain initial body weight. The diets were judged to be adequate in 
vitamins and essential minerals. The type of fat supplied by the diet was 
strictly controlled so that during the first dietary period 30% of the 
total calories were supplied by butter (Norco Co-Op., Blacktown, N.S.W., 
Australia); in the second dietary period the butter was substituted by a 
commercially available polyunsaturated margarine, P/S ratio > 3:1 (Sunbeam, 
Provincial Traders, Brisbane, Qld., Australia), again providing 30% of 
total calories. A proportion of the fat was used in the preparation of 
meals, and the remainder was consumed as a spread in the conventional 
manner. The cholesterol content of the margarine-enriched diet was 
supplemented with spray-dried egg yolk (Egg Marketing Board, N.S.W., 
Australia) to equal that contained in the butter-enriched diet 
(approximately 450 mg/day). The fatty acid compositions of the butter and 
margarine were determined by GLC and are given in Table 3.1.
The SF (butter) regimen was of 2 weeks duration (n = 12) and the PUF 
(margarine) regimen was of either 2 weeks (n = 12) or 4 weeks (n = 8).
Blood samples were obtained at four dietary intervals: day 0, prior to 
dietary manipulation; day 14, after 14 days of SF; day 28, 14 days after 
changing from SF to PUF; day 42, after a further 14 days of PUF.
3.2.3 Analysis of data
Data were analysed using Student’s "t" test for paired samples.
Linear regression and correlation coefficients were determined as described 
by Armitage (1971).
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Table 3.1
Approximate fatty acid compositions (% total) of 
butter and margarine used as fat supplements
Fatty Acid Butter Margarine
2-14:0 20 < 1
16:0 28 8
16:1 3 < 1
18:0 14 8
18:1 30 25
18:2 (n-6) 1 55
20:3,:4 ,: 5 < 1 < 1
Others 4 4
3.3 RESULTS
3.3.1 Serum lipids
The effects of dietary fat type on serum lipids is shown in Figure 
3.1: triglyceride levels showed a significant and progressive fall during
both dietary regimens; cholesterol levels showed no change after 14 days 
of SF. However, after 14 days of PUF there was a highly significant fall 
(4.3-3.5 mmol/1; p < 0.001). No further decrease was observed after an 
additional 14 days of PUF.
3.3.2 Platelet counts
Figure 3.2 shows the alterations in platelet counts of PRP and whole 
blood during the two dietary periods. The platelet count of PRP showed a 
significant increase (339-371 x lO^/pl; p < 0.01) on the SF diet, 
followed by a decrease (371-319 x 10-Vpl; P < 0.001) after 14 days of 
PUF. The platelet count remained unchanged after a further 14 days of PUF. 
The platelet count of whole blood showed an opposite, although
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insignificant, trend between days 0 and 14. There was a fall in the whole 
blood platelet count between days 14 and 28 (261-237 x 10^/yl; p < 0.01) 
but, with a further 14 days of PUF this returned to the level observed 
after 14 days of SF (237-262 x 10-Vpl; p < 0.05).
3.3.3 Platelet count ratio
The PCR (Figure 3.3) remained constant during the SF diet but 
increased from 0.84 to 1.0 during the first 14 days of PUF (p < 0.001) and 
remained at 1.0 during the subsequent 14 days of PUF consumption. 
Correlation between the serum cholesterol concentration and the PCR was 
poor (r = -0.24).
3.3.4 Platelet lipids
Figure 3.4 shows that of the four major classes of phospholipid in 
platelets only sphingomyelin and phosphatidyl choline showed significant 
changes in fatty acid profiles. DHGLA/behenate (20:3/22:0) and 
arachidonate/erucate (20:4/22:1) both showed significant rises between days 
14 and 42 in sphingomyelin. The phosphatidyl choline fatty acids showed a 
greater perturbation in response to diet. Between days 14 and 42 palmitic 
acid (16:0) decreased from 28.5% to 22.1% (p < 0.01), stearic acid (18:0) 
increased from 13.5% to 16.8% (p < 0.05), oleic acid (18:1) decreased from 
22.9% to 20.5% (p < 0.01) and linoleic acid (18:2), which showed the 
greatest change after PUF feeding, increased from 9.7% to 16.6% (p <
0 . 0 0 1 ) .
3.3.5 MPA production
Despite the changes in fatty acid composition of certain 
phospholipids, production of MDA by collagen-challenged platelets did not 
alter throughout the two dietary regimens (Table 3.2)
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Figure 3.1 The effect of diet on serum lipids
The effect of 14 days SF (days 0-14) followed by 14 days PUF (days 14-28) 
and a further 14 days PUF (days 28-42) on serum cholesterol and 
triglyceride (mean -  SD).
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Figure 3.2 The effect of diet on platelet counts
The effect of SF followed by PUF on platlet number in whole blood and PRP 
(mean ± SEM).
* p < 0.05; ** p < 0.01; *** p < 0.001 with respect to preceding value.
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Figure 3.3 The effect of diet on the platelet count ratio 
Response of the platelet count ratio to 14 days SF (days 0-14) followed by 
14 days PUF (days 14-28) and a further 14 days PUF (days 28-42). 
p < 0.001 between days 14 and 28, and days 14 and 42.
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Figure 3.4 The effect of diet on platelet phospholipid fatty acid patterns 
Fatty acid composition of the major phospholipids from platelets on day 0
(open bars); on conclusion of SF diet, day 14 (dotted bars); and on 
conclusion of PUF diet, day 42 (solid bars). Fatty acids are given as % of
total, excluding those contributing less than 1%.
p < 0.05
** p < 0.01 compared to preceding value
k k k p < 0.001
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Table 3.2
The effect of diet on MDA production by collagen-stimulated platelets
p-j^et MDA production
(nmol/10^ platelets)
0 Saturated 1.18 ± 0.44
14 Saturated 1.29 ± 0.48 NS
28 Polyunsaturated 1.24 ± 0.28 NS
42 Polyunsaturated 1.33 ± 0.48 NS
MDA production was determined after addition of collagen (6.25 pg/ml) to 
1.5 ml PRP stirred at 37°C for 4 min. Results are expressed as the mean ± 
SD; NS, not significantly different from any of the values.
3.3.6 Xa inhibitory activity
Table 3.3 shows no significant change in the Xa inhibitory activity of 
citrated PPP on either of the two dietary regimens.
Table 3.3
The effect of diet on the Xa inhibitory activity of citrated PPP
Day Diet % Factor Xa inactivated
0 Saturated 59.4 ± 9.1
14 Saturated 55.0 ±10.4 NS
28 Polyunsaturated 56.8 ± 8.0 NS
42 Polyunsaturated 56.0 ± 8.0 NS
Residual Xa activity was assessed by a clotting assay after preincubation 
of diluted test plasma with a reference solution of factor Xa. Results are 
expressed as mean ± SD; NS, not significantly different from any of the
values.
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3.3.7 Platelet release products
Figure 3.5 illustrates the changes in PF4 level and the HTCT of 
citrated PPP associated with each diet. The HTCT showed a small, but 
non-significant fall after 14 days of SF. The PF4 content of citrated 
PPP during this period showed a small, but non-significant increase. After 
changing to PUF the HTCT increased from 100% to 128% (p < 0.01), the 
subsequent 14 days of PUF having no further significant effect on the HTCT. 
PF4 levels apparently decreased after 14 days of PUF and increased after 
a further 14 days, but neither of these changes were statistically 
significant.
The apparent inverse relationship between the HTCT and PF4 
concentration in citrated PPP suggested in Figure 3.5 is demonstrated in 
Figure 3.6, the correlation coefficient (r) being -0.62 (p < 0.01). The 
regression indicates a 13% change in the HTCT per 100 ng of PF4. Figure
3.7 shows the effect of additions of exogenous PF4 on the HTCT of 
citrated PPP; the regression indicates ar 14% change in the HTCT per 1000 
ng of PF4 added.
Figure 3.8 compares the levels of PF4 and ß-TG found in ETP PPP 
during the two dietary regimens; SF had no significant effect on PF4 or 
8-TG; however, after changing the diet from SF to PUF, PF4 levels showed 
a decrease from 7.0 to 5.5 ng/ml (p < 0.05) between days 14 and 28 which 
was maintained during the subsequent 14 days of PUF. When day 14 was 
compared with day 42 a more statistically significant decrease was found (p 
< 0.01). Dietary PUF had no significant effect on ß-TG levels.
In Figure 3.9 the concentrations of PF4 in PPP prepared from blood 
collected into citrate or ETP are compared and it is evident that the 
levels of PF4 in ETP PPP are much lower than those found in citrated PPP. 
However, despite the lower levels of PF4 in ETP PPP the trends associated 
with dietary changes were found to be similar to those in citrated PPP.
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Figure 3.5 The effect of diet on the HTCT and PF4 content of citrated PPP
The PF4 (--- ) content of citrated PPP was measured by a specific RIA and
also as a function of its HNA by the HTCT (-- —).
Results are expressed as the mean ± SEM.
** p < 0.01.
NS, not significantly different from the preceding value.
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r = _0.62 P < 0.01 n=32
PF4 (ng/ml)
Figure 3.6 The correlation between PF4 levels and the HTCT of citrated * 
PPP
The regression indicates a 13% change in the HTCT/100 ng PF4.
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Figure 3.7 The effect of added PF4 on the HTCT of citrated PPP 
Mean ± SD of four experiments in which PF4 was added to citrated PPP and 
the HTCT determined. The results indicate a 14% change in the HTCT/1000 ng 
PF4. The thrombin clotting time (--- ) was performed in the absence of
heparin.
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Figure 3.8 The influence of diet on the PF4 (----) and ß-TG (--- )
levels of ETP PPP
PF4 and ß-TG were measured by RIA of ETP PPP.
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Figure 3.9 The effect of blood collection procedure on the PF4 levels 
of PPP
Comparison of levels of PF4 in citrated (--- ) and ETP (---- ) PPP and the
influence of diet upon these levels. Results are expressed as the mean ±
SEM. * p < 0.05; ** p < 0.01; NS, not significantly different.
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3.4 DISCUSSION
This study both reinforces and extends previous investigations 
indicating that platelet function and composition may be altered by dietary 
means. The greatest changes in function were evident during consumption of 
PUF. Since the subjects’ normal diet contained predominantly SF before 
starting the initial 2 week period of SF intake, the relative stability in 
cholesterol levels and platelet activity during this period is not 
unexpected. During the period of PUF ingestion there was an increase 
in the PCR (i.e. less circulating platelet aggregates). Regardless of 
whether or not this test reflects in vivo platelet aggregate formation, or 
platelet susceptibility to aggregation caused by the sampling procedure, 
the increase in the PCR suggests decreased platelet reactivity. The PCR 
and the serum cholesterol level appeared to be inversely related, but 
statistical analysis revealed only a poor correlation (r = -0.24). Wu et 
al. ( 1975) reported an increase in platelet aggregates in 
hypercholesterolaemic monkeys; however, they suggested that aggregate 
formation was secondary to vascular injury in the hypercholesterolaemic 
animals whereas our results suggest a more direct effect of PUF on the 
platelet itself. The results presented here show that PUF feeding resulted 
in a relatively small drop in serum cholesterol and a decrease in platelet 
aggregates evident after 2 weeks, whereas Wu et al. reported a much greater 
decrease in cholesterol concentration and a 6 week lag before there was a 
significant decrease in platelet aggregates. It is interesting to note 
that all PCR values, irrespective of diet, fall within the range previously 
reported for normal populations (Gjesdal et al., 1976; Prazich et al., 
1977). This normal range may reflect dietary habits as it does not appear 
to be related to age, sex or recent fasting state (Prazich et al., 1977).
The platelet counts in whole blood reflect the actual change that 
dietary manipulation has caused in circulating platelet number (as opposed
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to counts in PRP). A significant decrease in number was observed after 14 
days of PUF consumption, but after a further 14 days of PUF the levels 
returned to the post SF level. These observations are difficult to 
interpret. In similar human studies PUF was reported to decrease 
circulating platelet number (Mustard and Murphy, 1962; O’Brien et al., 
1976a) or have no significant effect (Hornstra et al. 1973).
It is important to realize that in the preparation of PRP a variable 
platelet concentration and population may be obtained depending on diet.
The trends are not the same between whole blood and PRP and this may be 
circulating in the blood. 0* Brien et al. ( 1976a) have reported that 
platelet loss from whole blood during PRP preparation is smaller after PUF 
feeding.
The observation that the HTCT was prolonged after ingestion of PUF is 
in agreement with O'Brien et al. (1976a) who demonstrated a similar trend 
after dietary enrichment with PUF. A longer HTCT is indicative of reduced 
HNA of the citrated plasma. This has been taken to be an indication of 
decreased in vivo platelet release of PF4 which has HNA. However, it is 
possible that an alteration in the HTCT could occur independently of PF4 
release; although PF4 is specific to the platelet, HNA may not be.
Indeed, it has been reported that factors such as lipoproteins (Bleyl e_t 
al., 1974), a 1-acid glycoprotein (Andersen and Godal, 1977), erythrocytes 
(Poplawski and Niewiarowski, 1965), and lysosomal proteins (Saba et al., 
1968; Hawiger et al., 1969) all have HNA. The results shown in Figure 3.5 
and 3.6 suggest that the observed changes in HNA have been contributed to 
by released PF4 since there is a strong relationship between the HTCT and 
PF4 levels of citrated PPP. These findings are consistent with PF4 
contributing HNA to the plasma, thereby leading to a shorter HTCT; the 
correlation between the two parameters attained a level of -0.62. This 
value is in agreement with figures published by Gjesdal (1974) who
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demonstrated a similar relationship between plasma PF4 concentration and 
HNA. The regression line in Figure 3.6 indicates a 13% decrease in the 
HTCT per 100 ng of PF4.
In the test system using citrated PPP and additions of purified PF4 
it was found that adjustment of the PF4 content by similar magnitudes to 
those shown in Figure 3.5 were insufficient to account for the observed 
attenuation of the HTCT; 1000 ng of PF4 were required to reduce the HTCT 
by 14%, which is approximately one order of magnitude greater than the 
value obtained from Figure 3.6. It therefore appears that the HTCT 
reflects additional factors with HNA; possible sources of 
platelet-independent HNA were referred to above. The possibility also 
exists that during preparation of the highly purified PF4 changes may 
have occurred which resulted in diminished heparin-neutralizing properties 
of PF4. The correlation of -0.62 would support this view, but would also 
support the suggestion that other heparin-neutralizing factors are released 
for the platelet in parallel with PF4. ß-TG has reported to have weak 
HNA; although not measured in citrated PPP in this study, the amounts 
usually released in association with PF4 would be unlikely to have 
sufficient HNA to account for the disparity.
The substantial change in the linoleic acid (18:2) content of the 
phosphatidyl choline fraction of platelet phospholipids is consistent with 
a previous study of PUF feeding and platelet composition (Nord^y and 
R^dset, 1971b). Linoleic acid was the major fatty acid in the 
polyunsaturated margarine used during the PUF regimen. Palmitic acid 
(16:0) also showed significant changes in phosphatidyl choline which could 
be related to levels in the dietary fats; the margarine, which contained 
less palmitic acid than the butter, resulted in lower levels in 
phosphatidyl choline. The fact that phosphatidyl choline showed the most 
significant changes in fatty acid profile accords with the observation of
Lewis and Majerus (1969) who found phosphatidyl choline to be the most 
metabolically active of the platelet phospholipids and may explain its 
higher susceptibility to the influence of dietary fats. It also contains 
substantially more linoleic acid than any of the major phospholipids, 
regardless of diet. Unfortunately the GLC conditions employed did not 
separate DHGLA (20:3) from behenic acid (22:0) or arachidonic acid (20:4) 
from erucic acid (22:1). DHGLA and arachidonic acid are metabolites of 
linoleic acid and are also capable of influencing platelet behaviour by 
conversion to prostaglandins and thromboxanes. Sphingomyelin showed a 
significant increase in the arachidonic acid/erucic acid fraction after PUF 
feeding; previous studies suggest that the major fatty acid in this 
fraction is erucic acid (Nord^y and Lund, 1968).
Despite changes in the fatty acid composition of the platelet 
phospholipids after PUF feeding there were no apparent effects on 
prostaglandin synthesis as determined by collagen-induced MDA production.
It is conceivable that alteration of the phospholipid fatty acid patterns 
could alter the release and/or metabolism of arachidonic acid, the 
metabolites of which contribute to collagen-induced aggregation. Although 
MDA production during platelet aggregation is a commonly used technique its 
use has been questioned, with the conclusion that little is known of the 
mechanisms of MDA production (Ali et al., 1977; Minkes et al., 1977). 
Therefore, re-examination of the possible effects of diet on platelet 
arachidonic acid metabolism using more refined techniques now available, 
which allow detailed quantitation of arachidonic acid metabolites produced 
during platelet aggregation, is required.
A recent publication by Nord^y and Svensson (1979) suggests that 
endothelial cells may mediate the effects of linoleic acid on platelet 
reactivity. In addition to other PUFA, linoleic acid was shown to be able 
to stimulate the production of prostacyclin-like activity by cultured human
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endothelial cells. If a similar effect occurs in vivo it may contribute to 
the platelet inhibitory actions of dietary PUF containing linoleic acid.
No significant changes in the Xa inhibitory activity of citrated PPP 
could be detected at any dietary interval which suggests that the 
previously reported effects of dietary fat on coagulation were on the 
procoagulant, as opposed to Xa inhibitory, aspect of the pathway (Mustard 
and Murphy, 1962; Nord^y, 1965; Renaud and Gautheron, 1975).
It is also noteworthy that despite an alteration in HNA and PF4 
levels there was no change in Xa inhibitory activity which is extremely 
sensititve to trace amounts of heparin (Biggs et al., 1970; Damus et al., 
1973). These observations may be in accord with the suggestion that free 
heparin is not present in the blood (Engelberg, 1977); if it was, Xa 
inhibitory activity might be expected to be influenced by fluctuations in 
HNA or PF4 . However, it may be possible to improve the sensitivity of 
plasma heparin assays (and perhaps detect free heparin in plasma) by 
choosing an alternative plasma preparation procedure which minimizes the 
release of HNA, as opposed to citrated plasma in which most heparin assays 
are performed (Teien and Lie, 1975).
In conclusion it appears that a diet rich in SF, which is a feature of 
developed countries, may result in the activation of circulating platelets. 
This in part may contribute to the initiation and development of 
atherosclerosis and thrombosis both of which are intimately concerned with 
the development of obstructive vascular disease. It is also apparent that 
the activation associated with a predominantly SF diet may be decreased by 
replacement of SF with PUF. Whether or not such replacement results in a 
significant reduction in the rate of cardiovascular disease remains to be
answered.
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3.5 SUMMARY
Twelve healthy male subjects were maintained on a SF dietary regimen 
followed by a PUF regimen. At selected intervals a number of tests were 
carried out to assess the effects of SF or PUF on platelet composition and 
activation. Concomitant with the fall in serum cholesterol associated with 
the PUF diet, there was a decrease in the number of circulating platelet 
aggregates and also a decrease in the HNA of citrated PPP, which could not 
be totally accounted for by PF^. "Circulating" PF4 , but not B-TG, was 
also present in significantly lower levels after PUF feeding. These 
observations are consistent with a reduction of in vivo platelet reactivity 
associated with the intake of a PUF diet. MDA production was unchanged 
throughout the dietary manipulations. Changes in the quality of dietary 
fat were manifested in the phospholipid fraction of platelet lipids, 
particularly in phosphatidyl choline. Platelet counts of whole blood were 
significantly decreased when subjects were consuming PUF, but not all of 
these alterations were reflected in PRP. The factor Xa inhibitory activity 
of citrated PPP was not affected by dietary changes.
CHAPTER 4
THE EFFECT OF POSTPRANDIAL 
ALIMENTARY LIPAEMIA ON HUMAN
PLATELET FUNCTION
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4.1 INTRODUCTION
The consumption of a fat containing meal is followed by an elevation of 
the plasma lipid content during the absorptive stage of digestion. The 
majority of the plasma lipid is in the form of chylomicra and the transient 
increase in the plasma content of chylomicra following a fat containing 
meal is known as postprandial alimentary lipaemia (PPAL). A recent review 
by Zilversmit (1979) evaluates the evidence for PPAL playing a role in 
atherogensis and concludes "In persons who do not have familial 
hyperlipoproteinemia atherogenesis may occur during the postprandial 
period".
Several studies of the effect of PPAL on human platelet function may be 
in accord with the conclusions reached by Zilversmit. Nord^y et al.
(1974) found that 2 hours after the consumption of a meal containing 
substantial amounts of either SF or PUF, the PF4 content of citrated PPP 
(assessed by changes in the HNA of PPP) had increased significantly but the 
PF3 activity of PRP had decreased. These observations were apparent 
after the SF meal but not after the PUF meal; it was also demonstrated 
that the type of dietary fat was reflected in the fatty acid composition of 
the plasma triglycerides.
Gjesdal (1974b) also demonstrated increased PF4 (HNA) in citrated PPP 
after a SF meal. O'Brien et al. (1976b) reported increased PF4 (HNA) and 
decreased antithrombin activity during SF-PPAL, but during PUF-PPAL PF4 
(HNA) decreased and antithrombin activity increased in citrated PPP. 
Baghurst et al. (1977) reported an increase in the rate of in vitro human 
platelet aggregation during SF-PPAL, but no effect on the extent of 
aggregation, fibrinolysis or the thrombin clotting time. Recently Johnston 
et al. ( 1979) reported a decrease in platelet count, an increase in 
circulating platelet aggregates and an impaired response of platelets to
ADP 3 hours after the consumption of SF.
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Thus, it would appear that there is some evidence for SF-PPAL inducing 
platelet activation and PUF-PPAL having no, or the opposite, effect. 
However, from the methodology employed it is apparent that there is little 
data on the in vivo effects of PPAL on human platelet function. Assay of 
the HNA of citrated PPP cannot be taken to be an index of in vivo PF4 
release (Chapter 3). In view of these facts a study was undertaken to 
assess the effects of SF- or PUF-PPAL on human platelet function including 
methods which are thought to reflect in vivo platelet activation. These 
included: RIA of PF4 and $-TG in ETP, CTP and citrated PPP;
determination of the PCR as an index of circulating platelet aggregates; 
assay of the HNA, by the HTCT, of CTP and citrated PPP. CTP was used in an 
attempt to determine whether the HTCT was affected by PPAL at in vivo 
concentrations of PF4, ETP and citrated PPP not being suitable for such 
determinations.
4.2 MATERIALS AND METHODS
4.2.1 Subjects
Nine healthy, non-smoking male volunteers aged 23-31 years (mean 25.8 
years) were studied over a 3 week period. No medications were consumed 
during the study period or for 2 weeks prior to its commencement.
4.2.2 Diet
SF or PUF was administered in milk shakes based on flavoured skim-milk. 
The SF milk shake was enriched with 152 g of lipid in the form of cream 
(400ml; Dairy Farmers Co-operative Ltd., Griffith, A.C.T., Australia) and 
the PUF milk shake was enriched with 150 g of lipid in the form of 
sunflower oil (170 ml; Meadowlea, Vegetable Oils Pty. Ltd., Footscray, 
Victoria, Australia). A control fat-free (FF) milk shake was also 
incorporated into the study, composed of the flavoured skim-milk without
added lipid.
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4.2.3 Experimental design
Platelet and lipid studies were initially performed after a 12 hour 
overnight fast. The subjects then consumed the appropriate milk shakes and 
after 2 hours the platelet and lipid studies were repeated. During the 2 
hour period the subjects were allowed to continue their normal 
(non-strenuous) daily activities.
The design of the study was such that on each day of the investigation 
three subjects were studied, each having one of the three milk shake types. 
Blood samples were withdrawn from the subjects within 5 min of each other 
and processed simultaneously. This design was selected to obviate day to 
day variation in experimental conditions. Full details of the protocol are 
given in Table 4.1.
Table 4.1
Design of study to examine the effects of PPAL on platelet function
WEEK 1 WEEK 2 WEEK 3
SUBJECT DAY DAY DAY
1 2 3 1 2 3 1 2 3
1 PUF - - SF - - FF -
2 SF - - FF - - PUF -
3 FF - - PUF - - SF -
4 - FF - - PUF - - SF
5 - PUF - - SF - - FF
6 - SF - - FF - - PUF
7 - - SF - - FF - PUF
8 - - FF - - PUF - SF
9 — — PUF . — — SF FF
4.2.4 Sampling of PPP
All samples of PPP were removed from below the chylomicron-rich
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fraction of lipaemic plasma samples and from the corresponding fraction of 
non-lipaemic plasma.
4.2.5 Analysis of data
Data were analysed using Student's "t" test for paired samples.
4.3 RESULTS
4.3.1 Serum lipids
The effects of the three test meals on serum lipids are shown in Figure 
4.2. Serum cholesterol levels were not affected by any of the three test 
meals. Serum triglycerides were elevated after both the meals containing 
fat; SF resulted in an increase of 1.22 mmol/1 (1.19-2.41 mmol/1, p <
0.01) and PUF resulted in an increase of 0.57 mmol/1 (1.21-1.78 mmol/1, p < 
0.01). Although there was an apparent difference in the extent of PPAL, 
SF-PPAL and PUF-PPAL triglyceride levels were not significantly different. 
The FF meal had no effect on serum triglycerides.
Table 4.2
The effect of PPAL on serum lipids
Diet Cholesterol^ Triglyceride^
pre 4.69 ±1.16 1.19 ± 0.48
SF NS **
post 4.57 ± 1.21 --- 2.41 ± 1.33
r pre 4.71 ± 1.21 NS 1.21 ± 0.42
PUF NS **
post 4.60 ± 1.32 --- 1.78 ± 0.42
pre 4.77 ± 1.07 1.24 ± 0.44
FF NS NS
post 4.60 ± 1.32 1.13 ± 0.36
1 mmol/1 (mean ± SD); ** p < 0.01; NS, not significantly different.
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4.3.2 Platelet counts
Figure 4.1 shows the effects of PPAL on the platelet count in whole 
blood; SF-PPAL resulted in a significant increase of 12 x lO^/yl 
(218-230 x 10-Vyl, p < 0.001); PUF-PPAL resulted in a similar, but less 
significant increase in the platelet count of 14 x lO^ /yl (217-231 x 
10^/yl, p < 0.05). The FF meal had no effect on the platelet count.
4.3.3 Platelet count ratio
The effects of the three meals on the PCR are shown in Figure 4.2 and 
it is apparent that SF-PPAL, PUF-PPAL and the FF meal had no effect on the 
platelet aggregate content of blood as determined by the PCR.
4.3.4 HTCT of citrated and CTP PPP
It is apparent that SF-PPAL, PUF-PPAL and the FF control had no 
significant effect on the HTCT of either citrated PPP (Figure 4.3) or CTP 
PPP (Figure 4.4). It is of interest to note that the mean HTCT of CTP PPP 
(179.3 ± 1.7%) was 1.16 x greater (p < 0.001) than that of citrated PPP 
(154.8 ± 1.4%) indicating that there was 13.7% less HNA in the CTP PPP.
4.3.5 PF4 levels of citrated, CTP and ETP PPP
The RIA of PF4 in citrated PPP (Figure 4.5), ETP PPP (Figure 4.6) and 
CTP PPP (Figure 4.7) revealed no significant difference between fasting and 
postprandial levels of PF4 for any of the three meals.
The mean concentration of PF4 was lowest in ETP PPP (3.2 ± 0 . 1  
ng/ml); the CTP PPP level (4.0 ± 0.1 ng/ml) was 1.3 x higher than ETP (p < 
0.001) and the citrated PPP level 140.1 ± 4.8 ng/ml) was 43.8 x higher than 
ETP (p < 0.001).
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SATURATED POLYUNSATURATED FAT FREE
Figure 4.1 The effect of PPAL on platelet counts in whole blood 
Results are expressed as mean + SEM.
* p < 0.05; *** p < 0.001.
NS, not significantly different.
SATURATED POLYUNSATURATED FAT FREE
f  0.9-
Figure 4.2 The effect of PPAL on the platelet count ratio 
Results are expressed as mean + SEM.
NS, not significantly different.
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SATURATED POLYUNSATURATED FAT FREE
Figure 4.3 The effect of PPAL on the HTCT of citrated PPP 
Results are expressed as mean + SEM.
NS, not significantly different.
Figure 4.4 The effect of PPAL on the HTCT of CTP PPP 
Results are expressed as mean + SEM.
NS, not significantly different.
, mean value for each anticoagulant
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Figure 4.5 The effect of PPAL on the PF4 level of citrated PPP
Figure 4.6 The effect of PPAL on the PF4 level of ETP PPP
All values are given as the mean + SEM. 
NS, not significantly different.
• , mean value for each anticoagulant.
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4.3.6 The ß-TG levels of citrated, ETP and CTP PPP
The effects of the three meals on plasma levels of ß-TG were similar to 
the effects on PF4 levels. There was no significant difference between 
the fasting and postprandial state in citrated PPP (Figure 4.8), CTP PPP 
(Figure 4.9) and ETP PPP (Figure 4.10).
The mean concentration of ß-TG was lowest in ETP PPP (26.6 - 0.3 
ng/ml); the CTP PPP level (34.9 - 0.9 ng/ml) was 1.3 x higher than ETP (p < 
0.001) and the citrated PPP level (1207 ± 34.2 ng/ml) was 45.4 x higher 
than ETP (p < 0.001).
4.4 DISCUSSION
Consumption of the meals containing substantial amounts of SF or PUF 
was followed by an increase in serum triglycerides with no effect on serum 
cholesterol; there was no significant difference in the extent of lipaemia 
caused by the SF or PUF. The stability of serum cholesterol levels and the 
extent of PPAL are in accord with previous studies of a similar nature 
(Nord^y et al., 1974; Baghurst et al., 1977).
Associated with the increase in serum triglyceride levels was a small, 
but significant, increase in the platelet count in whole blood. These 
findings are in contrast to those presented by O’Brien et al. (1976b) who 
reported a decreased platelet count during SF- and PUF-PPAL; however, 
these workers enumerated platelets in PRP, and as demonstrated previously 
(Chapter 3) platelet counts in PRP are not representative of the 
circulating number. The possibility of chylomicra being counted as 
platelets exists, however the calibration of the automatic cell counting 
device was such that particles below lpm in diameter were not counted, 
chylomicrons being 30-500 nm (Jackson et al., 1976) fall below the lower 
counting threshold of the machine and as such, would not be counted. The 
mechanism by which the number of circulating platelets increases during
PPAL is not known.
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Figure 4.8 The effect of PPAL on the g-TG level of citrated PPP
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Figure 4.9 The effect of PPAL on the ß-TG level of ETP PPP
SATURATED POLYUNSATURATED FAT FREE
PRE POST PRE POST PRE POST
Figure 4.10 The effect of PPAL on the ß-TG level of CTP PPP
All values are given as mean + SEM.
NS, not significantly different.
mean value for each anticoagulant
84
Platelet function tests conducted before and during PPAL failed to 
provide any evidence for platelet activation during PPAL; there was no 
evidence to suggest that intravascular platelet aggregation took place 
during SF-PPAL as determined by the PCR; this is in contrast to the 
observations of Johnston et al. (1979) who, using similar methodology, 
reported an increase in platelet aggregates 3 hours after a meal rich in 
SF. These workers also demonstrated that aggregate formation could be 
prevented by the administration of aspirin 12 hours prior to the test meal. 
An explanation for this difference in observations is not forthcoming.
This study also failed to confirm an increase in the HNA of citrated 
PPP during SF-PPAL as reported by Gjesdal (1974b), Nord^y et al. (1974) 
and O'Brien et al. (1976b); a possible explanation for the disparity in 
findings may lie in the plasma preparation procedures employed. In this 
study all plasma samples tested were harvested from below the 
chylomicron-rich layer which accumulated during the centrifugation 
procedures employed in the preparation of PPP. Citrated PPP was ultimately 
prepared by high speed centrifugation (8000 g) of the blood fraction 
remaining after prior removal of the PRP fraction (prepared at 100 g). The 
previous findings were based on citrated PPP prepared by centrifugation of 
whole blood or PRP which contained the full complement of platelets and it 
is reasonable to assume that platelet activation and release occurs in such 
a system. The previous workers also used a much lower g force to produce 
PPP (1000-1900 g) and reported platelet counts to be 0-10 x 10-Vul 
(O'Brien et al. 1976b) or 8-10 x 10-Vul (Gjesdal, 1974b). Nord^y et al. 
(1974) also employed techniques identical to those of Gjesdal. A g force 
of 8000, as used in this study, resulted in a platelet count of < 1 x 
10^/ul. Thus, it is possible that the previous observations may have 
resulted from:
(i) The presence of chylomicra;
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(ii) Variable in vitro release of platelet factors;
(iii) The presence of a variable number of platelets.
Nevertheless, if the previously reported increase in HNA did result from 
platelet release during sample preparation it may reflect a tendency 
towards increased platelet reactivity during SF-PPAL.
There was no evidence of altered platelet activity during PUF-PPAL 
which agrees with the observations of Nord^y et al. (1974), but disagrees 
with those of O'Brien et al. (1976b) who reported a decrease in the HNA of 
citrated PPP during PUF-PPAL. The previous discussion of possible reasons 
for disparate findings may also be applicable in the PUF-PPAL state.
The use of HNA as an indicator of plasma PF4 activity, and thereby 
platelet activity, is questionable as there are numerous platelet- 
independent factors which have HNA (Section 3.4), of particular importance 
in this type of study is the observation that lipoproteins have HNA (Bleyl 
et al., 1974); during PPAL there are substantial changes in plasma 
lipoproteins which might result in altered HNA independent of PF4. Thus 
the specific RIA of PF4 and B-TG are of particular interest and relevance 
in this study.
The data resulting from the .RIA of PF4 and B"TG are in agreement with 
the other observations reported here; there was no evidence of in vivo 
platelet activation, the PP4 and B-TG levels showing no significant 
difference between the fasting and postprandial state. Nord^y et al. 
(1974) and Gjesdal (1974b) reported increased HNA during SF-PPAL but could 
find no significant difference in the HNA of platelets, these observations 
together with the PF4 data presented above adds weight to the evidence 
for the reported HNA associated with SF-PPAL being derived from factors 
other than PF4.
Two other reports which briefly examined the effects of PPAL on human
platelet function appear to agree with the above findings. Although not 
describing the dietary regimens employed, Prazich et al. (1977) found no 
change in the number of circulating platelet aggregates during PPAL, and 
Rasi (1979) found that PPAL did not affect the concentration of ß-TG in ETP 
PPP. ,
The use of CTP as an anticoagulant would appear to be a useful 
collection procedure for the study of plasma factors when minimal release 
of platelet factors into plasma is required. Although CTP is slightly less 
effective than ETP, the PF^ and ß-TG levels being 1.3 x higher in CTP PPP 
than ETP PPP, it is much more effective than the use of citrate alone as an 
anticoagulant which results in a 43.8-45.4 fold increase in PF4 and ß-TG 
release in vitro. The use of citrate, as opposed to EDTA, in combination 
with theophylline and PGE\, allows clotting assays to be performed. In 
previous experiments it was found that EDTA, by chelation of Ca^+ , 
decreased the anticoagulant effect of heparin in the HTCT. Theophylline 
and PGE^, when added to plasma, have no effect on the HTCT (Jakubowski,
J.A. and Ardlie, N.G., unpublished data).
In conclusion, it is apparent from this study that no evidence was 
found to support previous suggestions of SF- or PUF-PPAL affecting in vivo 
platelet activity in terms of platelet aggregate formation, altered HNA, or 
PF4 and ß-TG release.
4.5 SUMMARY
Platelet function and serum lipid studies were conducted on nine 
healthy male subjects before and 2 hours after three meals, two of which 
were rich in SF or PUF, and a third control meal which contained no fat. 
Platelet activity was assessed by determination of in vivo platelet 
aggregate formation, the HNA of PPP, and the PF4 and ß-TG levels of PPP.
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Serum triglyceride levels increased significantly after the
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fat-containing meals but were unaffected by the FF meal. Serum cholesterol 
levels were not affected by any of the three meals. The platelet count of 
whole blood increased significantly after both SF and PUF, but was 
unaffected by the FF meal. Platelet function tests could not detect any 
alteration of in vivo platelet activation in terms of platelet aggregate 
formation, the HNA of PPP or PF4 and 8-TG release.
CHAPTER 5
THE EFFECT OF TYPE H a  HYPERLIPIDAEMIA ON THE
COMPOSITION AND CYCLIC AMP STATUS OF HUMAN PLATELETS
Ü U
5.1 INTRODUCTION
The possession by platelets of the enzyme adenylate cyclase, with the 
consequent ability to produce cyclic AMP, is thought to be an important 
aspect of the control of platelet function as cyclic AMP is a potent 
inhibitor of platelet aggregation and secretion. A key role for adenylate 
cyclase in platelets has emerged with the discovery by Moncada and 
colleagues of the ability of human vasculature to produce prostacyclin 
(PGI2). PGI2 was found to possess potent platelet inhibitory activity 
and it was subsequently demonstrated that the inhibitory effect of PGI2 
was mediated by elevation of cyclic AMP in the platelet. Thus, PGI2 
production and action is at least one defence mechanism enabling normal 
vasculature to control the accumulation of platelets, and the possible 
existence of circulating PGI2 may also prevent the production of 
circulating platelet thrombi.
PGE^ and PGD2, both of which may be produced by the platelet, have 
similar, although less potent, inhibitory activities to PGI2. However, 
the significance of the platelet's ability to produce PGEj and PGD2 is 
poorly understood. The production, actions and significance of PGI2,
PGD2 and PGE^ have been discussed earlier (Sections 1.2.7.1; 1.2.7.2).
Evidence suggests that hyperlipidaemia, particularly 
hypercholesterolaemia, is associated with enhanced platelet activity.
Nord(6y and R^dset (1971a) have presented evidence that patients with 
hyperbetalipoproteinaemia have abnormalities of platelet lipids; the total 
phospholipid content of the platelets was significantly elevated, which 
could account for the observed increase in PF3 activity of the platelets.
In a similar population Carvalho et al. (1974) could not confirm the 
increase in PF3 activity of platelets, but did report both a marked 
increase in platelet responsiveness to adrenaline, collagen and ADP, and
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increased release of platelet nucleotides. Joist et al. (1979) reported 
increased PF3 activity of PRP obtained from hypercholesterolaemic 
subjects but little difference in platelet sensitivity to aggregation 
induced by ADP, adrenaline or collagen; however, the hypercholesterolaemic 
subjects did have shorter bleeding times compared to the control 
population. Thus, despite some inconsistencies the general trend appears 
to be towards heightened platelet activity associated with 
hypercholesterolaemia.
It would appear from compositional data that platelet lipids may be 
influenced by the plasma in which the platelets circulate; modification at 
the megakaryocyte level is also feasible, but as yet, uninvestigated. 
Whatever the mechanism, platelet lipids can be altered by diet (Chapter 3) 
and possibly by hyperlipidaemic states. Shattil et al. (1977) reported 
that subjects with type Ila hyperlipidaemia had an increased ratio of 
cholesterol to phospholipid (C/Pl ratio) of their platelets which 
correlated with the C/Pl ratio of their LDL. The same group also 
demonstrated that increasing the C/Pl ratio of platelets in vitro resulted 
in an impaired response by adenylate cyclase to the stimulatory effect of 
various agents including PGE^, manifested by a decreased production of 
cyclic AMP (Sinha et al., 1977).
These observations may have important in vivo consequences; if 
platelets are less responsive to the inhibitory actions of agents such as 
PGI2, which is similar in its mode of action to PGE^, then increased 
platelet-platelet and platelet-vessel wall interaction could occur. These 
consequences may be conducive to the development of obstructive vascular 
disease which is apparent in hyperlipidaemic subjects.
To investigate these possibilities a study of the ability of platelets 
to accumulate cyclic AMP under various conditions was undertaken. The 
investigation included platelets from type Ila hyperlipidaemic
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(hypercholesterolaemic) subjects and a control population with normal lipid 
values. The platelet C/Pl ratio was assessed as was the ability to 
accumulate cylic AMP in response to PGI2 , PGD2 and PGE^.
5.2 MATERIALS AND METHODS
5.2.1 Subjects
Thirteen male and four female subjects with no clinical evidence of 
cardiovascular disease were selected for the study on the basis of fasting 
total serum lipid levels. The subjects were provisionally classified as 
having type Ila hyperlipoproteinaemia on the basis of a fasting total serum 
cholesterol of > 6.4 mmol/1 and triglyceride of < 2.0 mmol/1. Confirmation 
of type Ila hyperlipoproteinaemia was achieved by assessment of the 
cholesterol and triglyceride content of the individual lipoproteins.
Normal subjects were age and sex matched to the type Ila population. A 
total serum cholesterol <6.4 mmol/1 and triglyceride <2.0 mmol/1 were the 
criteria for selection of control subjects. All subjects included in the 
study had taken no medications for at least two weeks prior to blood 
collection. Full details of subjects are presented in Table 5.1.
Table 5.1
Details of normal and type Ila subjects
Normal Type Ila P
n 17 17
Age 40.9 ± 10.3 41.1 ± 10.3 NS
% male 65 65
Total plasma 
cholesterol (mmol/1) 4.82 ± 1.08 7.48 ± 0.68 < 0.001
Total plasma 
triglyceride (mmol/1) 0.35 ± 0.54 1.52 ± 0.57 < 0.002
LDL cholesterol (mmol/1) 2.95 ± 0.84 5.43 ± 0.78 < 0.001
Data is expressed as mean ± SD; NS, not significantly different.
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5.2.2 Platelet handling
Platelets were washed free of plasma and resuspended as previously 
described (Section 2.1.1.3). The platelet counts were adjusted to 
approximately 4 x 10^/yl (range 3-5 x 10^/pl). Within this range the 
platelet counts of type Ila and respective control suspensions were 
adjusted to within 1 x 10^/pl of each other and processed simultaneously 
to minimize the effects of variation in experimental conditions.
5.2.3 Platelet incubations
One ml of the washed platelet suspension was placed in an Eppendorf 
microcentrifuge tube at 37°C and 100 yl of the reagent diluent (modified 
Tyrode's buffer) or prostaglandin solution was added. After 30 sec the 
reaction was terminated and platelets disrupted by the addition of 200 pi 
TCA (30% w/v in 0.1 M HC1) and the cyclic AMP content determined.
5.2.4 Prostaglandins
Aqueous prostaglandin solutions were used within 1-5 min of 
preparation and incubated with the two platelet populations within 15 sec 
of each other. The final concentration of each prostaglandin represents 
the lower, intermediate and upper point on the linear section of a 
dose-response curve determined for each prostaglandin during preliminary 
experiments.
5.2.5 Analysis of data
Data was analyzed by Student’s "t" test for paired samples.
5.3 RESULTS
5.3.1 Platelet lipids
On examination of Table 5.2 it is apparent that although small 
increases in total cholesterol and phospholipid were found in the platelets
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from type Ila individuals, statistically these did not differ from the 
normal population. The ratio of cholesterol to phospholipid was also 
similar in both platelet populations.
Table 5.2
Cholesterol and phospholipid status of platelets
pg lipid/10^ platelets (mean ± SD) 
Normal Type Ila
Cholesterol 12.23 ± 1.98 13.18 ± 1.95 NS
Phospholipid 36.49 ± 6.46 38.39 ± 7.69 NS
C/Pl ratio 0.348 ± 0.033 0.351 ± 0.056 NS
NS, not significantly different.
5.3.2 Basal platelet cyclic AMP levels
The unstimulated ("basal") levels of cyclic AMP in washed platelets 
from type Ila individuals were not significantly different from the normal 
values (Table 5.3)
Table 5.3
Basal levels of cyclic AMP in normal and type Ila platelets
pmoles/10^ platelets (mean t SD)
Normal Type Ila
16.12 ± 2.25 14.71 ± 1.96 NS
NS, not significantly different.
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5.3.3 PGI^-stimulated platelet cyclic AMP levels
Figure 5.1 shows the accumulation of cyclic AMP in washed platelets 
from each of the two groups in response to PGI2 and indicates a 
diminished response at each concentration of the prostaglandin in the type 
Ila platelets. However, these differences were only significant at a 
concentration of 1.8 ng/ml; at this concentration normal platelets 
accumulated 209.3 and type Ila platelets 172.9 pmoles cyclic AMP/10^ 
platelets (p < 0.05).
5.3.4 PGD^-stimulated platelet cyclic AMP levels
Similar results to those found with PGI2 were obtained when 
platelets were incubated with PGD2 (Figure 5.2). A significant 
difference (p < 0.05) was found at a PGD2 concentration of 18 ng/ml; at 
this level normal and type Ila platelets accumulated 206.3 and 167.1 pmoles 
cyclic AMP/10^ platelets respectively.
5.3.5 PGEt-stimulated platelet cyclic AMP levels
Figure 5.3 shows the response of normal and type Ila platelets to 
PGE^, the impaired response was found to be significant at both the upper 
and intermediate levels used. Differences in levels of cyclic AMP between 
normal and type Ila platelets were 131.2 and 102.3 respectively (p < 0.05) 
at 9 ng/ml; and 221.7 and 185.9 respectively (p < 0.05) at 18 ng/ml.
It is of interest to note that despite the fact that PGI2 was used 
at concentrations one order of magnitude less than PGD2 or PGE^ the 
overall levels of cyclic AMP produced were similar.
5.4 DISCUSSION
No significant differences were found in the lipid composition of 
platelets between type Ila and normal subjects. This is in contrast to
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Figure 5.1 The response of platelet cyclic AMP levels to PGI? 
stimulation
Washed platelet suspensions from normal and type Ila subjects were 
incubated with three concentrations of PGI2 for 30 sec at 37°C and cyclic 
AMP accumulation measured.
NS, not significantly different.
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Figure 5.2 The response of platelet cyclic AMP levels to PGD9 
stimulation
Washed platelet suspensions from normal and type lla subjects were 
incubated with three concentrations of PGD2 for 30 sec at 37°C and cyclic 
AMP accumulation measured.
NS, not significantly different.
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P <0.05
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Figure 5.3 The response of platelet cyclic AMP levels to PGEi 
stimulation
Washed platelet suspensions from normal and type Ila subjects were 
incubated with three concentrations of PGEj for 30 sec at 37°C and cyclic 
AMP accumulation measured.
NS, not significantly different.
evidence presented by Shattil et al. (1977) who, using similar methods,
reported significant increases in both total cholesterol and the C/Pl ratio 
of platelets from type Ila subjects. These workers however, examined a 
population with much higher plasma cholesterol levels than the population 
reported here and this could account for our failure to note any alteration 
in the lipid content of platelets. Indeed, the same group in an earlier 
study of subjects with less severe hypercholesterolaemia failed to find 
significant differences in the absolute lipid content, but again 
demonstrated an increase in C/Pl ratio of type Ila platelets (Bennett jrt 
al., 1974). Further, Shastri et al. (1976) demonstrated quantitative and 
qualitative changes in the phospholipid content of platelets from type Ila 
subjects, but no abnormality in the cholesterol content or the C/Pl ratio.
Despite being unable to demonstrate changes in the cholesterol and 
phospholipid composition of platelets in type Ila subjects, an abnormality 
in the ability of the platelets to accumulate cyclic AMP in response to 
PGI2 , PGD2 and PGE^ was evident.
Adenylate cyclase, which is responsible for cyclic AMP production, is 
a membrane associated enzyme and one which in a number of systems has been 
shown to be influenced by its immediate lipid environment (Levey, 1973; 
Levey and Lehotay, 1976; Gazzotti and Peterson, 1977). The inability to 
demonstrate changes in the lipids of whole platelets in type Ila subjects 
does not exclude the possibility that focal changes in membrane composition 
may have existed in the hyperlipidaemic subjects. Shattil et al. (1977) 
observed that the total platelet C/Pl ratio of type Ila platelets tended to 
mask a greater abnormality of C/Pl ratio in the membrane fraction of type 
Ila platelets. Adenylate cyclase however, is not the sole factor governing 
cyclic AMP metabolism and accumulation. Cyclic AMP accumulation is a
function of production and degradation. Phosphodiesterase, the enzyme
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responsible for the catabolism of cyclic AMP may, by increased activity, be 
responsible for an impaired accumulation of cyclic AMP. However, studies 
of phosphodiesterase activity in situations similar to the one reported 
here have indicated normal enzyme activity (Sinha et al., 1977). Another 
possible explanation for diminished cyclic AMP accumulation is a decrease 
in the amount or availability of ATP which is the substrate for cyclic AMP 
production by adenylate cyclase.
It cannot necessarily be assumed that the impaired ability of 
platelets from type Ila subjects to accumulate cyclic AMP in response to 
prostaglandin stimulation is a primary effect of their lipid millieu. One 
must also bear in mind that type Ila subjects may have atherosclerotic 
lesions, although there was no overt clinical evidence of such. Such 
lesions may contain a number of substances which activate platelets (eg. 
connective tissue) and as a consequence type Ila platelets may be in a more 
reactive state than platelets in the normal population. These factors 
could account for the observed impairment in cyclic AMP accumulation in the 
platelets of the hyperlipidaemic subjects as it has been demonstrated that 
agents which induce aggregation, including those released from activated 
platelets, inhibit the elevation of cyclic AMP by such agents as PGE^ and 
PGI2 (Claesson and Malmsten, 1977; Gorman et al., 1977; Miller et al., 
1977). Thus, the abnormality reported may be a direct effect of 
hypercholesterolaemia on the platelet, or alternatively a secondary effect 
mediated by atherosclerotic lesions of the vessel wall. Nevertheless, this 
study has noted an impaired ability of platelets in type Ila subjects to 
accumulate cyclic AMP in response to three different prostaglandins.
PGI2 , and perhaps PGD2 (Oelz et al. , 1977; Smith et al., 1976b; Ali 
et al. , 1977), play important roles in controlling platelet reactivity; 
the role of PGE^ in vascular health, however, is unclear, although it has 
recently been demonstrated that platelets do contain PGE^ and its
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presence may play a role in controlling basal reactivity (Lagarde and 
Dechavanne, 1979).
The impaired responsiveness of the platelet to inhibitory stimuli in 
type Ila subjects may be conducive to the initiation of atherosclerosis by 
promoting platelet-vessel wall interaction if it is due to a primary effect 
of hypercholesterolaemia on the platelet. Alternatively, if the observed 
effects on cyclic AMP metabolism in the platelet are secondary to 
atherosclerotic lesions this may result in progression of the lesions and 
the development of thombosis. These conclusions assume that the findings 
reported here occur in vivo. The conditions employed involved extensive 
manipulation of the platelet populations prior to prostaglandin stimulation 
and the level of prostaglandin stimulation which resulted in an impaired 
response by the platelets from type Ila individuals may not occur in vivo. 
Nevertheless, these findings may be relevant to our understanding of the 
role played by the platelet in mediating vessel wall pathology caused by 
hypercholesterolaemia.
5.5 SUMMARY
Washed human platelet suspensions from seventeen type Ila 
hyperlipidaemic (hypercholesterolaemic) subjects were compared to those 
from seventeen age and sex matched controls with respect to lipid 
composition and ability to accumulate cyclic AMP.
No significant difference in platelet lipid composition was found in 
terms of total cholesterol, phospholipid or the ratio of cholesterol to 
phospholipid.
Basal levels of cyclic AMP in the platelets showed no significant 
difference between the two groups. Following interaction of platelets with 
PGI2 , PGD2 or PGE-[ and subsequent measurement of cyclic AMP type Ila
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platelets showed an impaired ability to accumulate cyclic AMP relative to 
controls.
Type Ila platelets exhibited a reduced ability to accumulate cyclic 
AMP at high concentrations of all three prostaglandins. At intermediate 
concentrations only PGEj could distinguish between the two groups and at 
low concentrations no significant difference in cyclic AMP accumulation was 
found between groups in response to any of the prostaglandins.
The inhibitory actions of PGl2> PGD2 and PGE^ on platelet 
activity, which are mediated by cyclic AMP accumulation in the platelet, 
are thought to be important mechanisms for the control of platelet-platelet 
and platelet-vessel wall interaction. The observation that platelets from 
type Ila hyperlipidaemic individuals show an impaired response to these 
three prostaglandins may be relevant to our understanding of the role 
played by the platelet in mediating vessel wall pathology caused by 
hypercholes terolaemia.
CHAPTER 6
EICOSAPENTAENOIC ACID AND
HUMAN PLATELET FUNCTION
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6.1 INTRODUCTION
Greenlandic Eskimos have been reported to be virtually free of CHD 
despite consuming a diet that is high in animal fat, containing 
approximately 40% of dietary calories, and animal protein, comprising 
approximately 25% of dietary calories (Dyerberg et al., 1975). This rich 
diet and freedom from CHD contrasts markedly with developed societies 
amongst whom the high incidence of CHD has been related to a diet similarly 
high in animal products.
Studies of Greenlandic Eskimos and a matched Danish population have 
revealed no striking differences in the P/S ratio of dietary or tissue 
lipids, but the Eskimos had a slightly higher intake of cholesterol. 
Analysis of plasma lipids in these two populations revealed lower total 
cholesterol and triglyceride levels and a beneficial ratio of HDL to LDL 
cholesterol in the Eskimos (Bang and Dyerberg, 1972; Dyerberg et al.,
1975). These latter observations may in part explain the reported absence 
of CHD in this community.
Dyerberg et al. (1975) also noted that the Eskimo's plasma lipids were 
enriched in long chain polyunsaturated fatty acids, notably 
eicosapentaenoic acid (EPA) which contributed up to 16% of total esterified 
fatty acids. It was suggested that EPA had hypolipidaemic properties which 
resulted in lower plasma lipids in the Eskimos compared to the Danish 
population who had little EPA in their plasma lipids.
The reason for the enrichment of Eskimo plasma lipids with EPA is 
reflected in their diet, the majority of which is obtained from their 
aqueous environment. Marine fish and mammals consumed by the Eskimos are a 
rich source of EPA (Bang et al., 1976). In contrast, land animals on which 
developed societies rely heavily for food, contain little EPA (Exler,
1975).
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More recently it has been suggested that in addition to possible 
hypocholesterolaemic properties, EPA may protect the Eskimo from 
atherosclerosis and CHD by other mechanisms. Dyerberg and Bang (1978) 
reported that EPA, when added to PRP, had the ability to inhibit subsequent 
aggregation induced by ADP, and they suggested that EPA was converted to 
prostaglandins and/or thromboxanes which inhibited platelet aggregation. 
Studies published concurrently with the work reported here have shown that 
the EPA-derived prostaglandin cyclic endoperoxides PGG3/H3 and 
thromboxane A3 (TXA3) could not induce platelet aggregation in contrast 
to their arachidonic acid-derived counterparts (Raz et al., 1977). Based 
on these observations Dyerberg and Bang suggested that EPA protected the 
Eskimo from CHD by its antiplatelet actions. The antiplatelet activity of 
EPA was subsequently confirmed and in addition it was demonstrated that rat 
arterial tissue was capable of converting EPA to a substance which could 
inhibit platelet aggregation. This substance was hypothesized to be the 
EPA-derived trienoic prostacyclin, namely PGI3 (Dyerberg et al., 1978).
To further evaluate the possible effects of EPA on human platelet 
function a detailed study on the effects of EPA on platelet aggregation and 
secretion was undertaken by using agents that might indicate its site(s) of 
action. The mechanism by which EPA, incubated with rat arterial tissue, 
inhibited platelet aggregation was also investigated.
6.2 MATERIALS AND METHODS
EPA was used as the potassium salt in all the experiments described. 
6.2.1 Platelet aggregation and secretion
The effect of EPA on platelet aggregation was initially studied using a 
dual channel aggregation module. This was achieved by adding 50 pi of the 
required EPA solution or the reagent diluent (50 mM Tris-HCl, pH 7.4) to 
the cuvette containing 500 pi of stirred citrated PRP at 37°C; after 3 min
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aggregation was induced by addition of the aggregating agent. When used, 
aspirin was added in 50 pi of reagent diluent 1 min before EPA. All 
experiments were repeated in a Lumi-Aggregometer which measures aggregation 
and the secretion of ATP simultaneously. Release of ATP was expressed as a 
% of the control value and platelet aggregation as the % light transmission 
(PRP = 10%, PPP = 90%).
6.2.2 Preparation of arterial tissue
Thoracic aortae from male Wistar rats (200-250 g) were obtained after 
sacrificing the animals by stunning and cervical dislocation. The aortae 
were immediately placed in ice-cold Tris-HCl (50 mM, pH 7.4) and washed 
free of blood. After removal of adventitial connective tissue, the 
arterial tissue was cut into 1-2 mm rings and five such rings were 
incubated at 37°C in 200 pi of 50 mM Tris-HCl, pH 7.4, which had previously 
been gassed with 5% CO2 in O2 . The tissue was incubated in this manner 
for 3 min after which time 50 pi of the incubation buffer (IB) was added to 
500 yl of the washed platelet suspension stirred at 37°C in the aggregation 
module. The platelet sample was challenged 1 min later with 50 pi of a 
collagen suspension, the concentration of which had previously been shown 
to aggregate appropriate control samples. After the IB had been shown to 
inhibit collagen-induced aggregation the arterial rings were washed 
successively until all anti-aggregatory activity was removed as evidenced 
by unimpaired aggregation. Washing consisted of 1 ml additions of IB, 
gently mixing for 30 sec and then discarding the buffer. Complete removal 
of endogenous anti-aggregatory activity was usually achieved after 25-35 
washes. Having removed endogenous activity the arterial rings were 
incubated with IB containing EPA (0.1 mM). After 3 min, the IB was tested 
for anti-aggregatory activity as described above for unwashed tissue.
Experiments were also performed to assess the effect of IB on platelet 
cyclic AMP levels. This was achieved by simultaneously adding 100 pi IB to
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1 ml of washed platelets under identical conditions to those described 
above. One min after addition 1 ml was removed and added to 200 pi of 
ice-cold TCA and assayed for cyclic AMP. The preparation of arterial 
tissue in this manner is a modification of previously described methods 
(Moncada et al., 1977a; Dyerberg et al. , 1978).
6.3 RESULTS
All results are representative of at least four experiments unless 
otherwise specified.
6.3.1 The effect of EPA on platelet aggregation and secretion
Figure 6.1 shows the effect of EPA on platelet aggregation and 
secretion of ATP induced by various agents. EPA completely inhibited the 
release reaction and the subsequent shape change and aggregation induced by 
collagen. However, the adhesion of platelets to collagen over a time 
course of 6 min was not inhibited by EPA. Maximum adhesion occurred after 
1 min and was 24% in the presence of EPA and 25% in the control experiment. 
Results were calculated as the % of platelets which had adhered to collagen 
at each time interval. The shape change (i.e. the initial decrease in 
light transmission) and the first phase of aggregation induced by low-dose 
ADP was decreased (Figure 6.2a). This inhibitory effect on the first phase 
of ADP-induced aggregation was minimized by prior incubation with aspirin 
(Figure 6.2b). The second phase of ADP induced aggregation and the release 
reaction were abolished by preincubation with EPA. Although the first 
phase of adrenaline-induced aggregation was apparent, the rate was notably 
retarded and again there was complete inhibition of the second phase of 
aggregation and release. Similar results were obtained with thrombin and 
arachidonic acid; EPA did not affect the shape change but eliminated 
subsequent aggregation and release. The control PRP clotted following 
aggregation with thrombin, whereas the PRP incubated with EPA did not clot 
during the course of the experiment. Aggregation and release induced by
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F i g u r e  6 .1  The e f f e c t  of  EPA on p l a t e l e t  a g g r e g a t i o n  and s e c r e t i o n  
EPA ( 0 . 4 6  mM) or r e a g e n t  d i l u e n t  (RD) was added 3 min b e f o r e  v a r i o u s  
a g g r e g a t i n g  a g e n t s  and t h e  f i n a l  c o n c e n t r a t i o n s  of  a g e n t s  were as  f o l l o w s :  
c o l l a g e n  (COLL), 0 .41  p g / m l ;  ADP, 0 .3 6  yM; a d r e n a l i n e  (ADR), 0 .4 2  pM; 
t h ro m b in  (THR), 0 .09  U/ml; a r a c h i d o n i c  a c i d  (AA), 0 . 4 6  mM; A23187, 12.5  
jj M.
The s e c r e t i o n  of  ATP i s  i n d i c a t e d  a t  t h e  end o f  e ach  t r a c i n g  and i s  
e x p r e s s e d  a s  a % of  t h e  c o n t r o l  v a l u e .
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the ionophore A23187 was also completely inhibited by EPA but again shape 
change was unaffected. Depending on the stimulus employed it was found 
that maximum inhibition of aggregation and release was obtained 1-2? min 
after the addition of EPA. The inhibition was of a competitive nature and 
could be reduced by increasing the concentration of agent or decreasing the 
concentration of EPA.
Figure 6.3 shows the effect of EPA on aggregation and release in PRP 
induced by the cyclic endoperoxide analogue U46619, the aggregatory 
properties of which have recently been described in detail (Best et al., 
1979). Shape change was unaffected but subsequent aggregation and release 
were inhibited (Fig 6.3a). In the presence of aspirin (Fig 6.3b) the 
inhibitory effects of EPA on U46619-induced aggregation were virtually 
abolished.
6.3.2 The effect of EPA on aggregation and cyclic AMP content of washed 
platelets
Figure 6.4 shows that the inhibition of aggregation induced by EPA was 
concentration dependent; aggregation was significantly inhibited at an EPA 
concentration of > 23 pM, at increasing concentrations the inhibition 
became progressively greater and statistically more significant. The 
cyclic AMP content of the washed platelet suspension was not significantly 
increased from basal levels (16.8 -  7.1 pmoles/lO^ platelets) until the 
EPA concentration reached 360 pM (30.0 -  4.8 pmoles/10^ platelets (p < 
0.05); at 460 pM EPA, cyclic AMP increased to 38.1 ± 11.6 pmoles/10^ 
platelets (p < 0.001).
6.3.3 The metabolism of EPA by arterial tissue
Figure 6.5 shows the results of a typical experiment in which 
aggregation induced by collagen was studied following the addition of IB in 
which arterial tissue had been incubated before and after washing. The
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(a) (b)
Figure 6.2 The effect of EPA on the first phase of ADP induced aggregation
(a) EPA (0.46 mM) or RD was added 3 min before a low dose of ADP (0.15 UM).
(b) In the presence of aspirin ASA (4.6 mM) added 1 min before EPA or RD.
(a) (b)
Figure 6.3 The effect of EPA on aggregation and secretion induced by 
U46619
(a) In the presence of aspirin (ASA); (b) after incubation with ASA for 1
min prior to addition of EPA or RD. Final concentrations of reagents were 
as follows: EPA, 0.46 mM; U46619, 4.6 pM; ASA, 4.6 mM. The secretion of
ATP is given as a % of the control value.
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Figure 6.4 The effect of EPA on collagen-induced aggregation and cyclic 
AMP
Results of seven experiments (mean ± SD) in which platelets were incubated
with EPA for 3 min and assayed for cyclic AMP (--- ). In three of the
seven experiments platelet aggregation (----), induced by collagen (0.2
pg/ml), was studied at the time samples were removed for cyclic AMP 
determination.
* p < 0.05; ** p < 0.01; *** p < 0.001 (with respect to basal cyclic AMP
or maximal aggregation).
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levels of cyclic AMP found in the washed platelets at the time of collagen 
challenge are also included. Figure 6.5b shows complete inhibition of 
collagen-induced aggregation with an associated elevation of cyclic AMP 
after IB from unwashed arterial rings was added to platelets 1 min before 
challenge. Figure 6.5c shows that after being washed 25 times, the 
arterial tissue failed to produce this prostacyclin-like activity.
The effect of arterial tissue washed free of endogenous 
prostacyclin-like activity and then incubated with IB containing EPA is 
shown in Figure 6.6a; EPA appears to have been converted to a material 
with prostacyclin-like activity as demonstrated by impaired platelet 
aggregation and elevated cyclic AMP. Subsequent incubation of the arterial 
tissue in EPA free IB did not result in the production of prostacyclin-like 
activity (Figure 6.6b).
6.4 DISCUSSION
The results presented here indicate that EPA has an inhibitory effect 
on various aspects of platelet aggregation and release. EPA mainly 
affected the second phase of aggregation which is related to the release 
reaction. EPA influenced the platelet shape change and partially inhibited 
the first phase of ADP induced aggregation in the absence of aspirin. This 
effect was reduced in the presence of aspirin, suggesting that, at least in 
part, EPA was exerting its inhibitory effect on the first phase of 
aggregation via the cyclo-oxygenase pathway. Current theory holds that 
aggregation and the release reaction are partly mediated by metabolites of 
arachidonic acid, namely PGG2 > PGH2 and/or TXA2 , which are produced 
after platelet activation. It is therefore not unreasonable to suggest 
that the inhibitory effect of EPA on the second phase of platelet 
aggregation is also mediated by this pathway. EPA is structurally similar 
to arachidonic acid and is known to be the precursor of trienoic 
prostaglandins and thromboxanes (Needleman et al., 1976; Raz et al.,
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Figure 6.5 The effect of EPA and IB on collagen-induced aggregation and 
cyclic AMP levels of washed platelets
(a) EPA 9 yM or RD was added 1 min prior to collagen.
(b) RD or IB from unwashed arterial rings (5 x 1 mg rings) was added 1 min 
before collagen.
(c) RD or IB from arterial rings washed 25 times was added 1 min prior to 
collagen.
The collagen (COLL) concentration in each experiment was 0.28 yg/ml. 
Numbers in boxes indicate cyclic AMP levels 1 min after addition of RD or 
IB, results are expressed as pmoles/10^ platelets.
I l l
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Figure 6.6 The effect of IB containing EPA on collagen-induced
aggregation and cyclic AMP levels of washed platelets
(a) IB containing EPA after incubation with washed arterial tissue.
(b) Lack, of endogenous prostacyclin-like activity after removal of added 
EPA by two further washes of the arterial rings in EPA-free IB.
Concentration of EPA in IB and RD was 0.1 mM.
Collagen (COLL) concentration in washed platelets was 0.28 Pg/ml.
Numbers in boxes show cyclic AMP levels 1 min after addition of EPA-RD or 
EPA-IB, results are expressed as pmoles/10^ platelets.
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1977). Further evidence to support this hypothesis is presented in Figure
6.3 in which EPA is shown to have an inhibitory effect on aggregation and 
secretion induced by the endoperoxide analogue U46619. However, when the 
cyclo-oxygenase pathway was blocked by prior incubation with aspirin, the 
inhibitory effect of EPA on U46619~induced aggregation and secretion was 
almost abolished. It therefore appears that cyclo-oxygenase is involved in 
the inhibitory actions of EPA; further, at the concentration used in PRP 
(0.46 pM) it is metabolized to substances which are actively 
antiaggregatory. If EPA was acting solely by occupation of cyclo-oxygenase 
without being metabolised, one would not expect inhibition of the first 
phase of ADP- or U46619~induced aggregation as they are not dependent on 
cyclo-oxygenase involvement.
Using labelled EPA, Needleman et al. (1979) have recently 
confirmed that human platelets are capable of synthesizing PGH3 and 
TXA3. They also demonstrated that these compounds were capable of 
inhibiting PGH2» TXA2 and collagen-induced aggregation. Evidence was 
presented which suggested that these inhibitory actions were mediated by an 
increase in platelet cyclic AMP. These observations are in accord with the 
findings and discussion presented above. However, it appears from Figure
6.4 that inhibition of collagen-induced platelet aggregation by EPA cannot 
be totally accounted for by an increase in cyclic AMP. A graded inhibition 
of aggregation by EPA is apparent, but only higher levels of EPA
( > 360 pM) are associated with significant cyclic AMP elevation which may 
account for the total inhibition of aggregation.
A possible explanation for these results is that when EPA is present at 
low concentrations it binds to cyclo-oxygenase and antagonizes the 
metabolism of arachidonic acid, which mediates collagen-induced 
aggregation. As EPA concentrations increase, PGG3/H3 and TXA3 are 
produced in small amounts and occupy subsequent enzyme or receptor sites 
(no evidence for this hypothesis has been presented); at the upper
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concentration range of EPA, PGG3/H3 and TXA3 are produced in amounts 
sufficient to stimulate adenylate cyclase, or possibly inhibit 
phosphodiesterase, resulting in the elevation of cyclic AMP and further 
inhibition of aggregation. Support for this hypothesis has been presented 
by Needleman et al. (1979) who reported efficient binding of EPA to 
cyclo-oxygenase, but poor metabolism, compared to arachidonic acid.
The production of a prostacyclin-like substance after incubating EPA 
with arterial tissue is in accord with a report by Dyerberg et al. (1978) 
who suggested that the product was PGI3. Results presented here have 
added weight to this hypothesis since this antiaggregatory substance had 
properties similar to PGI2 in terms of its ability to elevate platelet 
cyclic AMP. The possibility of EPA inducing endogenous PGI2 production 
must be considered; however, Dyerberg et al. (1978) investigated this 
possibility and could find no evidence to support it. Needleman et al. 
(1979) demonstrated that aortic microsomes converted PGH3 to PGI3 and 
this could be blocked by 15-hydroperoxyarachidonic acid, which is a 
selective inhibitor of prostacyclin synthesis. They also confirmed the 
above observations that PGI3 was capable of increasing platelet cyclic 
AMP levels and inhibiting aggregation. Comment was also made on the 
possible production of PGE3 and PGD3 by platelets and/or arterial 
tissue; these aspects require further elucidation as production of these 
substances by platelets could account for the elevation of cyclic AMP that 
was apparent at the upper concentration range of EPA.
Although the above results, as well as those reported by others, may be 
relevant to the reported low incidence of CHD in Greenlandic Eskimos, one 
must also include a lower exposure to traditional risk factors as playing a 
part in the relative immunity to CHD. Nonetheless, these factors cannot 
readily explain the reported bleeding tendency amongst Greenlandic Eskimos 
(Dyerberg and Bang, 1979) which occurs despite normal coagulation. The 
observation that Eskimo plasma and platelet lipids are enriched in EPA and
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that aspirin shortened an abnormally long bleeding time; are in accord 
with the in vivo metabolism of EPA to inhibitory substances (Dyerberg and 
Bang, 1979).
Thus, by inhibiting platelet aggregation and platelet-vessel wall 
interaction, EPA may play an important role in the lack of CHD amongst 
Greenlandic Eskimo populations and the reported bleeding tendency. It may 
also provide a lead to clinically useful antiplatelet agents.
6.5 SUMMARY
The effects of eicosapentaenoic acid (EPA) on human platelet 
aggregation and secretion were assessed. EPA was found to partially 
inhibit the first phase of ADP-induced aggregation and abolished the second 
phase of aggregation and secretion. Similarly, inhibitory effects were 
obtained when aggregation and secretion were induced by collagen, 
adrenaline, thrombin, arachidonic acid and the ionophore A23187. Aspirin 
markedly reduced the inhibitory effects of EPA on aggregation induced by 
ADP and the endoperoxide analogue U46619. Rat arterial tissue when 
incubated with EPA produced a substance which inhibited collagen-induced 
aggregation and also elevated the level of cyclic AMP in platelets which 
may explain its inhibitory action. It is suggested that the enzyme 
cyclo-oxygenase converts EPA to substances which inhibit platelet 
aggregation and secretion.
CHAPTER 7
GENERAL DISCUSSION AND CONCLUSIONS
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7.1 DISCUSSION
7.1.1 Factors affecting human platelet function and their implications
The findings presented in this thesis demonstrate that human platelet 
function may be altered by a number of factors which have been reported to 
be associated with either an increased or a decreased propensity towards 
atherosclerosis, thrombosis and CHD. In general terms those factors 
investigated which have been reported to accelerate CHD have been conducive 
to platelet activation. In contrast, those factors which would appear to 
protect against premature CHD have been shown to have the opposite effect 
on platelet activity.
Two investigations were performed to assess the effect of dietary SF 
and PUF on platelet function. Chapter 3 describes the effects of either 2 
weeks of SF or 4 weeks of PUF feeding on platelet function. The findings 
suggest that PUF feeding results in decreased in vivo platelet activity 
manifested by a decrease in the number of circulating platelet aggregates 
and a decrease in the PF4 content of ETP PPP. Decreased HNA of citrated 
PPP was also observed, but this cannot be regarded as an in vivo phenomenon 
as large amounts of PF^ and HNA are released in vitro in such a system; 
nevertheless, if the released HNA was solely derived from platelets it 
might still indicate a decreased tendency of the platelets to undergo the 
release reaction and hence platelet activation. Estimation of circulating 
platelet aggregates by the PCR, and RIA of PF4 in ETP PPP, are regarded 
as an index of in vivo platelet activity since in these procedures 
platelets are "fixed" as soon as is technically possible after removal from 
the circulation, thus preventing platelet aggregation and release in vitro.
Although an abundant literature exists on the platelet inhibitory
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activity of PUF, the mechanism by which this effect occurs is poorly 
understood. In an attempt to locate the site(s) of action of PUF, 
prostaglandin synthesis by PRP was assessed by the assay of MDA production, 
but no evidence was found to suggest that MDA production was impaired by 
PUF feeding. However, as discussed in Chapter 3 determination of MDA must 
now be regarded as a rather crude assay for prostaglandin synthesis and 
more refined techniques should be employed in such studies. It is 
pertinent to note that platelet phosphatidyl choline, the most abundant 
phospholipid in platelet membranes, was enriched in linoleic acid after the 
PUF diet. Perturbation of membrane lipids has been reported to affect the 
activity of membrane associated enzymes (Section 5.4) and an increase in 
the PUFA content of platelet membranes may be expected to result in an 
increased microviscosity (fluidity) of those membranes. Cyclo-oxygenase, 
thromboxane synthetase and lipoxygenase have been reported to be membrane 
bound (Ho et al., 1976, 1977) and consequently their enzymatic ability may 
be influenced by altered membrane fluidity induced by dietary manipulation. 
Farias et al. (1975) has reported altered enzyme activity of erythrocyte 
membranes by dietary manipulation of their lipid components. Thus, the 
dietary enrichment of platelet membranes with PUFA may result in altered 
cyclo-oxygenase, thromboxane synthetase or lipoxygenase activity all of 
which have been reported to control platelet activity. Adenylate cyclase 
is also membrane bound and could be similarly affected; indeed a decrease 
in platelet membrane fluidity induced by cholesterol incorporation results 
in decreased adenylate cyclase activity (Sinha et al., 1977).
In the light of present day knowledge it would be naive to discuss 
factors affecting in vivo platelet activity without considering the 
endothelial cell which, by the production of prostacyclin (and other 
factors), controls in vivo platelet activity. Thus, the endothelial cell
may mediate the inhibitory effects that PUF have on platelets. Nord^y
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(1979a) has recently investigated this possibility and observed a 
stimulation of the antiaggregatory activity of cultured endothelial cells 
in the presence of linoleic acid. Further investigations along similar 
lines may delineate an important role of the endothelial cell in mediating 
the influence that dietary fats have on platelet function.
The implication of these findings to the pathogenesis of 
atherosclerosis in people consuming SF diets are dependent on the platelet 
being involved in the initiation and progression of atherosclerosis and 
CHD, and there is strong evidence to support this hypothesis (Sections 
1.3.3.1, 1.3.3.2). In relation to the present findings it has been 
reported that platelet aggregates or platelet-fibrin aggregates may induce 
endothelial damage which is secondary to aggregate formation (Mustard and 
Packham, 1970; Jorgensen et al., 1970, 1973; Lough and Moore, 1972,
1973). The findings presented in Chapter 3 demonstrated a higher 
proportion of circulating platelet aggregates after SF feeding. It was 
also demonstrated that PF4 levels were higher after SF feeding; PF4 is 
released from the same a-granule as the PDGF which has been implicated in 
the proliferation of intimal SMC which is a characteristic of the 
atherosclerotic plaque (Section 1.3.2.1). A greater availability of the 
PDGF after SF feeding may result in stimulation of intimal SMC, especially 
if there are areas of exposed subendothelium. However, caution must be 
taken in this extrapolation as no studies on circulating PDGF have been 
carried out; secondly, no changes in circulating $-TG levels could be 
demonstrated after SF feeding, ß-TG being stored in the same a-granule as 
PF4 and the PDGF.
The relevance of PF4 release from the platelet is unclear. It is 
conceivable that PF4 neutralizes the effects of heparin-like sulphated 
mucopolysaccharides that are found on endothelial cells and which have
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anticoagulant effects similar to heparin (Section 1.2.3). A recent report 
has also demonstrated AT III to be present on the endothelial cell (Chan 
and Chan, 1979) and in combination with sulphated mucopolysaccharides may 
afford protection to the endothelium, protection that may be reduced by 
PF^ which has HNA. SF also resulted in an increased amount of HNA 
release (in vitro) relative to the PUF diet.
There are three publications which support the conclusions derived from 
the findings presented in Chapter 3. Miettenen et al. (1972) demonstrated 
that, in a 12 year cross-over study (The Helsinki Trial), increasing the 
P/S ratio of mental hospital patients resulted in a significant decrease in 
mortality from CHD. In the same group of patients Hornstra et al. (1973) 
subsequently assessed platelet function by use of the filtragometer and 
found a pronounced reduction in platelet reactivity after PUF feeding.
Renaud et al. (1978) studied platelet function in relation to dietary 
fats in farmers from two areas of France (Moselle and Var). It was 
reported that farmers from the Moselle area had significantly greater 
clotting and aggregatatory activity of PRP which correlated with their 
relatively higher SF intake. A higher incidence of CHD was also evident in 
the Moselle region compared to the Var region. Total plasma cholesterol 
levels were identical in both regions.
The Edinburgh - Stockholm study conducted by Logan et al. (1978) 
investigated a number of risk factors for CHD in an attempt to explain a 
three-fold higher mortality from CHD in Edinburgh men, aged 40 years, 
compared to corresponding Stockholm men. Although total serum cholesterol 
levels were not significantly different, exposure to other risk factors was 
higher in Edinburgh men. In addition it was found that Edinburgh men had a 
significantly lower relative linoleic acid content in their plasma and
adipose lipids.
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Interpretation of epidemiological data is a specialized field and its 
limitations must be recognized for example, causal roles are suggested, but 
not proven. Nevertheless, these three reports are consistent with the 
findings of Chapter 3, and suggest that dietary PUF results in a lower 
incidence of CHD as a result of decreased platelet reactivity.
The second investigation incorporating dietary manipulation involved 
the assessment of in vivo platelet activity during PPAL. This study was 
conducted in order to investigate previous reports of SF-PPAL leading to 
platelet activation and PUF-PPAL having the opposite effect. In addition 
the findings might have provided evidence for long term dietary 
manipulation of platelet activity being partly a result of intermittent, 
but frequent, platelet stimulation or inhibition, i.e. during the 
postprandial state which can be assumed to occur 3-4 times daily. However, 
no evidence of altered platelet activity could be found during SF- or 
PUF-PPAL. From this investigation it would appear that if atherogenesis is 
a postprandial phenomenon (Zilversmit, 1979) it is not a result of the 
direct effects of PPAL on platelets. The contradictory findings between 
this study and previous studies may be explained by the different 
methodological procedures employed, further discussion of which will 
follow.
Manipulation of the diet of healthy individuals provides useful 
information on the immediate effects of risk factors on platelet function. 
This is in contrast to the observations presented in Chapter 3 in which the 
ability of platelets from hypercholesterolaemic (type Ila) subjects to 
accumulate cyclic AMP in response to PGI2 , PGD2 and PGE| was studied.
The findings indicated that there was impaired cyclic AMP accumulation in 
the type Ila subjects compared to an age- and sex-matched control 
population with normal cholesterol levels. The results are consistent with 
activated platelets being associated with atherosclerosis and CHD in type
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Ila subjects. However, it was not possible to relate the findings to a 
direct effect of elevated plasma lipids on platelet function, particularly 
as there were no demonstrable changes in the type Ila platelet lipids. An 
alternative explanation relates to activation of platelets by factors such 
as exposed subendothelium, resulting from cholesterol-induced endothelial 
damage (Ross and Harker, 1976), or pre-existing atherosclerotic lesions 
which contain collagen and other substances which may also activate 
platelets. It has been demonstrated that activated platelets have an 
impaired ability to accumulate cyclic AMP (Section 5.4). This discussion 
can also be related to the majority of platelet studies in relation to risk 
factors for CHD when pre-existing lesions may be present and highlights the 
advantage of using healthy subjects as experimental models. Nevertheless, 
if PGI2 , PGD2 and PGE^ are involved in controlling platelet activity 
in vivo these findings are consistent with the suggestion that hyperactive 
platelets, possibly resulting from a primary and/or secondary effect of 
hypercholesterolaemia, are responsible for the initiation and/or 
progression of premature atherosclerosis and CHD resulting from increased 
platelet-platelet and platelet-vessel well interaction.
The final Chapter dealt with the effects of EPA on human platelet 
function and supports the exciting studies instigated by the Danish group 
of Dyerberg and Bang who, in 1975, reported that the plasma lipids of 
Greenlandic Eskimos were enriched in EPA. However, despite knowledge of 
the ability of EPA to be converted to trienoic prostaglandins since 1964 
(Bergstrom et al., 1964) it was only recently that these two observations 
were brought together when it was found that EPA could be converted by 
platelets to trienoic prostaglandins and thromboxanes and thereby lead to 
inhibition of aggregation (Dyerberg and Bang, 1978, 1979; Dyerberg et al., 
1978; Needlemen et al., 1979), which might explain the Eskimos resistance 
to CHD despite consuming a diet rich in animal fat and protein. The
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inhibitory actions of EPA appear to be two-fold; EPA can directly inhibit 
aggregation via the platelet's cyclo-oxygenase and thromboxane synthetase 
pathways, and can also be converted to PGI3 by arterial tissue, PGI3 
having inhibitory actions similar to PGI2. In a very recent report 
Gryglewski et al. (1979) also demonstrated an overall inhibitory effect of 
EPA on platelet aggregation, but in contrast to Needleman et al. (1979) 
provided evidence that TXA3 was proaggregatory and that PGE3 and 
PGD3, together with antagonism of the thromboxane receptor by EPA, were 
responsible for the inhibitory effects. Clearly, there is much more in 
vitro and in vivo work to be done to clarify the mode of action, and 
implications, of the inhibitory properties of EPA. The most recent report 
from Dyerberg and Bang (1979) has demonstrated that Eskimo platelet 
phospholipids are enriched in EPA at the expense of arachidonic acid and 
that aspirin shortened the bleeding time. These observations are all in 
accord with the hypothesis that EPA can be converted by the platelet to 
active inhibitory substances. This in vivo data may explain the reported 
bleeding tendency and low incidence of CHD in Greenlandic Eskimos, and adds 
weight to the evidence for platelets being involved in CHD. The 
implications from these observations for the dietary control of obstructive 
vascular diseases are interesting as EPA may be preferable to DHGLA which 
also has direct antiplatelet actions and has been suggested to be useful 
antiplatelet agent (Kernoff et al., 1977; Sim and McGraw, 1978). However, 
the observation that DHGLA cannot act as substrate for prostacyclin 
synthesis (Dyerberg et al., 1978) and actually inhibits PGI2 production 
by cultured human endothelial cells (Nord^y et al., 1979b) casts doubt 
upon this suggestion, a view shared by others (Gryglewski and Moncada,
1979).
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7.1.2 Methodology
From the findings presented and discussed it is clear that the 
procedures used for assessing platelet activity must be based on a sound 
knowledge of platelet function and once developed, those techniques must be 
performed in a standardized manner. This is exemplified in studies 
involving the measurement of platelet release products. To assess the in 
vivo levels of platelet-specific proteins one must use anticoagulants that 
contain antiplatelet agents; at present the most commonly used "cocktail" 
is ETP. The mode of action of ETP is two-fold; firstly it chelates 
Ca^+ , thus preventing coagulation and platelet aggregation; secondly it 
increases the intracellular level of platelet cyclic AMP, resulting from 
the stimulation of adenylate cyclase (by PGEj) and inhibition of 
phosphodiesterase (by theophylline). Increased intracellular cyclic AMP is 
one of the most efficient inhibitors of platelet aggregation and release. 
Use of ETP, high speed centrifugation and an avoidance of the upper and 
lower fractions of the PPP resulted in mean PF^ levels of 3.3 ng/ml and 
3-TG levels of 26.6 ng/ml PPP which were approximately forty-five times 
less than levels found in citrated PPP (Chapter 4). The slightly higher 
levels reported in Chapter 3 may be explained by the sampling of the upper 
PPP fraction which has been reported to be enriched in platelets (Rasi, 
1979); although different subjects and variation in protein standards must 
also be considered.
Although PF^ and ß-TG levels are relatively low in ETP PPP, it may be 
possible to improve the collection procedure by use of a more potent 
stimulator of adenylate cyclase (eg. PGI2) in combination with a more 
potent inhibitor of phosphodiesterase (eg. IBMX; 3-isobutyl-l- 
methylxanthine). It may also be possible to produce platelet-free plasma 
using methods similar to those of Wolf (1967) which results in plasma free 
of platelets and "platelet dust". However, these latter procedures are
time consuming and not to be recommended for routine assays but may provide 
useful in vivo information on the release of PF4 , 8-TG and other factors 
from platelets.
In view of the marked release of platelet constituents into citrated 
PPP, use of the HTCT must be questioned. However, the use of CTP, which is 
only marginally less effective than ETP, may still be applicable in the 
absence of the more refined technique of RIA. With lower levels of PF4 
it might be necessary to use a more sensitive assay for HNA such as those 
utilizing chromogenic substrates (Wohl et al., 1978). Perhaps the major 
disadvantage of measuring HNA as an indication of PF^ is the possible 
presence of numerous other factors with HNA.
Although this discussion of methodology has concentrated on platelet 
release products such consideration must be given to all techniques 
involving assay of platelet activity and subsequent extrapolation of the 
findings to in vivo phenomena.
7.2 CONCLUSIONS
The adoption of a diet with a high P/S ratio, as advised by public 
health authorities, would appear to have no adverse effects on platelet 
reactivity. In fact the associated decrease in platelet reactivity might 
be expected to result in a decreased incidence of obstructive vascular 
disease and so be in accord with the aims of the dietary recommendations. 
Study of the inhibitory actions of EPA adds weight to the hypothesis that 
platelet activity and CHD may be decreased by dietary factors and may prove 
to be an effective adjuvant for the dietary control of CHD.
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